

NOT TRANSFERABLE



JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.


(Public Sector Undertaking of the Government of Jammu and Kashmir)

Corporate Head Office: Plot No. 58, Friends Colony Satyam Road Trikuta Nagar Jammu

Corporate Office: Opposite J&K Motor Garage Deptt near Hajj House Bemina Srinagar

Telephone: 0191-2478842; 191-3510489 (Jammu), 0194-2490662 (Srinagar)

email: mdjkmscl2@gmail.com; **website:** www.jkmsclbusiness.com



E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR TESTING AND ANALYSIS OF DRUGS, MEDICINES, MEDICAL DEVICES, SURGICAL DISPOSABLES & SUTURES FOR THE YEAR 2024-2026

(REFERENCE NO: JKMSCL/ANALYTICAL TESTING LABS/2024/624

DATED: 03-04-2024



JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.

(Public Sector Undertaking of the Government of Jammu and Kashmir)

Corporate Head Office: Plot No. 58, Friends Colony Satyam Road Trikuta Nagar Jammu

Corporate Office: Opposite J&K Motor Garage Deptt near Hajj House Bemina Srinagar

Telephone: 0191-2478842; 191-3510489 (Jammu), 0194-2490662 (Srinagar)

email: mdjkmscl2@gmail.com; **website:** www.jkmsclbusiness.com

No. JKMSCL/ ANALYTICAL TESTING LABS/2024/624

Dated: 03-04-2024

NOTICE INVITING BID

On Behalf of Jammu & Kashmir Medical Supplies Corporation Limited, e-bid under two cover system (Technical bid in cover 1 and Financial bid in cover-2) is invited for the **Empanelment of Analytical Testing Laboratories for Testing and Analysis of Drugs, Medicines, Medical Devices, Surgical Disposables & Sutures for the year 2024-2026**. Detailed tender document may be downloaded at J&K Govt. Portal www.jktenders.gov.in, www.jkmsclbusiness.com,

The cost of the tender along with tender processing charges of Rs. 10,000/- (Rupees Ten thousand only/-) i.e. Rs.1,000/- (Rupees one thousand only) as cost of tender & Rs.9,000/- (Rupees Nine thousand only) as tender processing charges shall have to be paid either through NEFT in the Corporation's Bank Account No.0373040500000032 maintained at J&K Bank Limited, Branch Medical College Jammu, IFSC Code JAKA0MEDJAM or by depositing the amount directly into the above account no in favour of FA/Chief Accounts Officer JKMSCL drawn on any of the Scheduled / Nationalized bank Payable at Jammu/Srinagar.

- i. **Scanned copies of Bank transfer/deposit receipt or NEFT towards the cost of tender documents and Tender Processing charges shall have to be uploaded along with Technical Bid, failing which tender shall be outrightly rejected.**
- ii. EMD for Rs.1,00,000(One Lac only) as Bid Security for General in shape of FDR pledged to **Financial Advisor/CAO, JKMSCL** or through NEFT in the Corporation's Bank Account No.**0373040500000032**.
- iii. As per **General Financial Rules(GFRs) 2017**, Micro and Small Enterprises (MSEs) are **exempted** from submission of **Bid Security (EMD)**
- iv. **Not to submit the hard copy of technical bid physically.**

Sd/-

Managing Director

Jammu and Kashmir Medical Supplies Corporation Ltd.



JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.

(Public Sector Undertaking of the Government of Jammu and Kashmir)

Corporate Head Office: Plot No. 58, Friends Colony Satyam Road Trikuta Nagar Jammu

Corporate Office: Opposite J&K Motor Garage Deptt near Hajj House Bemina Srinagar

Telephone: 0191-2478842; 191-3510489 (Jammu), 0194-2490662 (Srinagar)

email: mdjkmscl2@gmail.com; **website:** www.jkmsclbusiness.com

No. JKMSCL/ ANALYTICAL TESTING LABS/2024/624

Dated: 03-04-2024

NOTICE INVITING BID (NIB)

- **IMPS mode of transfer is not verifiable and hence shall not be entertained as tender fee or tender processing charges. Bidders claiming to submit money through IMPS Mode shall be out-rightly rejected.**
- **DD as mode of payment for cost of tender/tender processing fees/Bid Security shall only be entertained if the same is deposited physically against proper receipt in the Corporate Office of JKMSCL, before the closing due date of e-bid.**
- **Bid Security Rs. 1,00,000.00 in the form of FDR/CDR/BG/RTGS/NEFT (FDR/CDR from scheduled/Nationalised Bank / BG from Nationalised Bank) with validity of 30 months. Bids submitted without sufficient bid security & validity shall be summarily rejected. **Firms which are registered as (Micro and Small Enterprise) MSEs Unit(s) as defined in MSE Procurement Policy issued by Department of Micro, Small and Medium Enterprises (MSME) shall be considered for Exemption of bid security including tender fee of Rs. 1000/- as per provisions of MSME Policy. Tender Processing charges of Rs. 9000/- is to be paid by the MSE Unit(s) also.****
- Physical hard copy of Bid Security in form of FDR/CDR/BG may be submitted to the Corporate Head Office before closing the due date of e-bid. Scanned copy of the same shall be uploaded along with Technical Bid, failing which bid shall be out rightly rejected.
- **The bidders seeking EMD exemption must submit the valid supporting document for the relevant category. Under MSE category only manufacturers for goods and service providers for services are eligible for exemption from EMD. Traders are excluded from the purview of this Policy.**
- **Scanned copies of NEFT/RTGS/Bank Transfer/Receipt towards the cost of tender documents and tender processing charges shall have to uploaded along with Technical Bid, failing which bid shall be out rightly rejected.**

Note: If any amendment is carried out in the bid specifications and terms & conditions following pre-bid meeting, the same shall be uploaded on the J&K Govt. tender portal www.jktenders.gov.in; JKMSCL website: www.jkmscl.nic.in; www.jkmsclbusiness.com, www.jkhealth.org.in; but shall not be published in any newspapers / journal.

In case any inconvenience is felt, please contact Corporate Office JKMSCL at Jammu/Srinagar or queries may be e-mailed on address mdjkmscl2@gmail.com, gmjjkmscl@gmail.com.

Sd/-
Managing Director
Jammu and Kashmir Medical Supplies Corporation Ltd.



JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.

(Public Sector Undertaking of the Government of Jammu and Kashmir)

Corporate Head Office: Plot No. 58, Friends Colony Satyam Road Trikuta Nagar Jammu

Corporate Office: Opposite J&K Motor Garage Deptt near Hajj House Bemina Srinagar

Telephone: 0191-2478842; 191-3510489 (Jammu), 0194-2490662 (Srinagar)

email:mdjkmscl2@gmail.com; **website:** www.jkmsclbusiness.com

(Bid form is non-transferable)

BID FORM FOR RATE CONTRACT OF" ANALYTICAL TESTING LABS -2024"

BID. No. JKMSCL/ ANALYTICAL TESTING LABS/2024/624

Dated: 03-04-2024

- | | | | |
|---|---|------------|--|
| 1. Date and time of publishing the bid | : | 12-04-2024 | at 1600 hrs |
| 2. Start date and time for download of the bid document | : | 12-04-2024 | at 1630 hrs |
| 3. Last date and time for download of the bid document | : | 14-05-2024 | upto 1600 hrs |
| 4. Clarification Start date | : | 12-04-2024 | from 1630 hrs |
| 5. Clarification end date | : | 23-04-2024 | upto 1000 hrs |
| 6. Pre-bid Meeting | : | 23-04-2024 | at 1100 hr
at Conference Hall JKMSCL, Jammu |
| 7. Start date and time for submission of online bids | : | 25-04-2024 | from 1000hrs |
| 8. Last date and time for submission of online bids | : | 14-05-2024 | upto 1600 hrs |
| 9. Date & time of online opening of Technical Bids | : | 16-05-2024 | at 1100 Hrs |
| 10. Cost of Tender Document | : | 1000/- | |
| 11. Tender Processing charges | : | 9000/- | |

The cost of the tender along with tender processing charges of Rs. 10,000/- (Rupees Ten thousand only/-) i.e. Rs.1,000/- (Rupees one thousand only) as cost of tender & Rs.9,000/- (Rupees Nine thousand only) as tender processing charges shall have to be paid either through NEFT in the Corporation's Bank Account No.0373040500000032 maintained at J&K Bank Limited, Branch Medical College Jammu, IFSC Code JAKA0MEDJAM or by depositing the amount directly into the above account no. **(IMPS money transfer shall not be entertained)**

i. **Scanned copies of Bank transfer/deposit receipt or NEFT towards the cost of tender documents and Tender Processing charges shall have to be uploaded along with Technical Bid, failing which tender shall be outrightly rejected.**

ii. EMD for Rs.1,00,000(One Lac only) as Bid security for General in shape of FDR pledged to Financial Advisor/CAO, JKMSCL or through NEFT in the Corporation's Bank Account No.0373040500000032.

iii. As per General Financial Rules(GFRs) 2017, Micro and small Enterprises (MSEs) are exempted from submission of Bid Security (EMD)

10. Bid Security (EMD) :
- Rs 1,00,000/- for general bidders
 - OEM Firms which are registered as MSEs shall be considered for Exemption of bid security including tender Charges of Rs. 1000/- as per provisions of MSEs Policy. Tender Processing charges of Rs.9000/- is to be paid by the MSE Unit(s) also.

11. ADDRESS FOR COMMUNICATION:

**Managing Director or General Manager,
J&K Medical Supplies Corporation Ltd,
Temp. Address- Plot No. 58, Friends Colony
Satyam Road Trikuta Nagar, Jammu/
Bemina Near Haj House- Srinagar (Kashmir)**

Important Note: No representation shall be allowed, accepted and entertained after the Pre-bid meeting. Bidders are requested to submit their queries/clarifications in advance so that the same can be discussed and clarified during the Pre-bid meeting. Also all the representations regarding the queries/clarifications shall be submitted to the email id: prebid.jkmscl@gmail.com, before the pre-bid meeting.

Declaration Form cum check list
Technical Bid Form
 (It should be notarized)

I/We..... (Name of Bidder) having our office at..... (Address of Bidder) do declare that I/We have read all the Terms & Condition of the bid floated by M.D., Jammu & Kashmir Medical Supplies Corporation Limited, Jammu / Srinagar (J&K) for the Rate Contract Cum Supply of “ ANALYTICAL TESTING LABS -2024” and agree to abide by all the Terms & Conditions set forth therein/SPP.

I/We declare that we are participating in this bid in the capacity of (Original Manufacturer/Direct Importer/ Authorized Representative). I/We enclose valid Manufacturing license/ acknowledgement/ Memorandum/IEM/ Registration of MSME Unit/Import license along with Authorization by Foreign Principal.

I/We further declare that the rates offered by us shall remain valid for the entire period of the rate contract and shall reduce the rates, if the rates are reduced for any other buyer within the Union of India during this period. I/We enclose the following documents serially as given below:

S.No	Item	Page No.
1.	Bid security declaration For General Bid Security for MSME Units is exempted	
2.	<p>a) For General Cost of Tender documents =Rs.1000/- Tender Processing charges=Rs.9,000/- Total =Rs.10,000/-</p> <p>b) For MSME Units Cost of Tender document- Exempted Tender processing charges= Rs.9,000/- Total = Rs.9,000/- (Through NEFT)</p>	
3.	Nature of the Firm/Public Company/Private Company/Partnership / Proprietorship/Any other with Documentary proof issued by the competent Authority.	
4.	Average Annual Turnover Statement not less than 50 lakhs for Last 3 financial Years from Chartered Accountant with UDIN (2021-22, 2022-22 & 2023-24).	
5.	Copies of Audited Balance Sheet & Profit Loss Account for last three financial years from Chartered Accountant (2021-22, 2022-22 & 2023-24).	
6.	Latest Non Conviction Certificate issued by the Licensing authority of the respective state (Issued not before 6 months).	
7.	List of clients for past 02 years	
8.	Copy of the PAN Card of the bidder	
9.	Copy of GST Registration Certificate of bidder	
10.	Certificate of NABL Accreditation	
11.	Certificate regarding adherence to uploaded Specifications (GLP Compliant, L1Certificate)	
12.	Acceptance to complete Analysis & reporting conditions	
13.	Latest GST Return of the bidder	
14.	Details of Technical personnel employed in the testing unit approved by the Licensing Authority.	

15.	Authorization letter nominating a responsible person of the bidder to transact the business with the Tender inviting Authority JKMSCL.	
16.	Name, photograph & specimen signature of the designated officer/ representative of the Bidder who is authorized to make correspondence with the JKMSCL.	1..... (Name & Signature) 2..... 3.....
17.	Declaration Cum Checklist (Annexure A)	
18.	Terms & Conditions of Bid and Rate contract (Annexure B)	
19.	List of Items highlighting the items quoted by the bidder (Annexure C)	
20.	Proforma for Annual Turnover statement of the Firm from Chartered Accountant with UDIN. (Annexure D) (2021-22, 2022-22 & 2023-24)	
21.	Proforma for performance Certificate (Annexure-E)	
22.	Declaration on Non Judicial Stamp Paper of Rs 100. (Annexure-F)	
23.	Details of the Drug Testing Laboratory (Annexure-G)	
24.	Laboratory Details (Personal in QC Department) (Annexure-H1)	
25.	Laboratory Details (Important Instruments/Equipments in Lab) (Annexure-H2)	
26.	Laboratory Details (Facilities in Microbiological Section) (Annexure-H3)	
27.	Laboratory Details (List of Reference Sample with date of the procurement) (Annexure-H4)	
28.	Proforma for Agreement (Annexure I)	
29.	Memorandum of Appeal. (Annexure J)	

INSTRUCTIONS TO BIDDERS

Annexure - B

Before filling up of bid or submission of the bid form, kindly go through the following instructions meticulously / carefully so that your bid shall not be considered as invalid:

1. TENDER PROCESSING FEES AND EMPANELMENT FEES.

- a) E- Tender under two cover system (Technical Bid in Cover – I & Financial Bid in cover– II) has been invited by The Jammu and Kashmir Medical Supplies Corporation Ltd, for **E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR TESTING AND ANALYSIS OF DRUGS, MEDICINES, MEDICAL DEVICES, SURGICAL DISPOSABLES & SUTURES FOR THE YEAR 2024-2026**
- b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiture of the Earnest Money deposit.

2. ELIGIBILITY CRITERIA FOR EMPANELMENT:-

- (1) Drug Testing Laboratories should have valid approval from Drug & Food Administration Department of the respective State/UT for quality testing of drugs, Medicines, Medical Devices, Disposables, Surgical & Sutures, it bids for (as per the provisions of the Drugs and Cosmetics Act, 1940 and Rules there under).
- (2) The laboratory should be GLP compliant under the provisions of Drugs and Cosmetics Act, 1940 and Rules there under and/or also notified under MDR 2017.
- (3) It should hold schedule L-1 certificate i.e should have NABL accreditation with proper scope of accreditation / notification under MDR 2017 to undertake testing of drugs, surgical and sutures it bids for.
- (4) The laboratory should have at least three years standing in the test & analysis of the items it bids for.
- (5) The laboratory should have an average annual turnover of not less than Rs.50.00 lakhs towards testing drug, medicines, surgical and suture items testing services during preceding three financial years
- (6) The lab should have undertaken test and analysis of drugs, medicines, surgical & suture item and supplies of at least three government institutions /corporation/reputed manufacturers during the preceding three financial years
- (7) The lab (including prop/partner/directors) should not have been banned / debarred/convicted or blacklisted by any State or Central Government Organization or its central procurement agencies on the due date of bid submission.
- (8) The laboratory should have all necessary instruments/equipments/machines for testing of medical devices, drugs, medicines, surgical & sutures as per standards laid down in Drugs &Cosmetics Act / Pharmacopoeia / Bureau of Indian Standards/ Medical Devices and other standards as applicable/ desired with minimum three working HPLSCs.

3. TECHNICAL BID:-

The Bidder must upload the following under technical bid:-

- (a) Bidders may quote for anyone item or more as mentioned under the list of Drugs, Medicines, Surgical & Sutures placed as Annexure-C).
- (b) The bidder laboratory has to mention the types of test for each item to be carried out by it, as per the annexure.
- (c) The bidders shall upload scanned copy of all the financial instruments
- (d) Attested Photocopy of Compliance of Schedule L-1 of Drugs & Cosmetics Rules, 1945 (GLP certificate) duly renewed up to date, issued by the State Licensing Authority and or notification of the laboratory under MDR 2017.

(Copy of NABL accreditation with details of scope for testing of Drugs, Medicines, Surgical & Sutures.)

- (e) Details of analysis of Drugs, Medicines, Surgical & Suture carried for the last three years as per proforma given as Annexure E.
- (f) List of important clients for whom tests have been conducted during the past 3 years.
- (g) Attested copy of certificate of registration for service tax.
- (h) Non- Conviction Certificate by the State Licensing Authority/ competent authority .
- (i) Annual turnover statement for previous 3 financial years i.e. duly certified by Chartered Accountant
- (j) Copies of the Audited Balance Sheet and Profit and Loss Account for previous three financial years duly certified by Chartered Accountant
- (k) Following information to be given in Annexure H1 to H4.
 - a) The list of qualified personnel employed in the laboratory with proof of their qualifications and relevant approvals.
 - b) The list of instruments/equipments available in the laboratory specifying the brand, year of manufacture and the list of tests it is utilized for.
 - c) Microbiological facilities available in the laboratory.
 - d) List of reference samples along with their date of procurement and quantities, wherever required.
 - e) A declaration in the performa given in Annexure F duly signed and notarized.
 - f) Details of Laboratory in Annexure – G.
 - g) A copy of PAN issued by Income Tax Department.
 - h) Documentary evidence for the constitution of the company / concern

4. PRICE BID:-

The price bid shall also be known as financial document and every bidder shall have to submit its price in excel format (BOQ) provided in tendering portal **www.jktenders.gov.in**. The template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only. The bidder should quote rate for the complete tests as applicable to the item. The rate for sterility test for sterile products should also be quoted separately at last entry of BOQ. All the cells of BOQ should be carefully filled. In case the bidder does not wish to quote / bid for any test/item, he/she should leave the concerning cell blank. In case of any cell being blank, it would be assumed that the laboratory does not wish to quote / bid for that particular test / service/item. In case the bidder wishes not to charge for any service or test, he/she should clearly write "0 (ZERO)" in the cell. In case any cell has the value"0 Zero", it shall be assumed that the Laboratory wishes to provide the service / test, but is not charging for it.

5. TECHNICAL AND FINANCIAL EVALUATION:-

The valid Technical bids shall be scrutinized by the committee constituted for the purpose and Financial Bids of only those who qualify in the Technical Bid after scrutiny thereof, including inspection of the laboratory as per schedule L-1 (GLP), if required, shall be opened. Date for opening of Financial Bid shall be declared after opening of technical Bid and the venue shall be Corporate Head Office Jammu/Srinagar.

6. EARNEST MONEY DEPOSIT:-

Earnest money deposit shall be pledged to FA& CAO JKMSCL for not less than 30 months. EMD of unsuccessful bidders shall be refunded after allotment of contract in favour of successful bidders.

7. GENERAL CONDITIONS:-

The details of the Drugs, Medicines, Surgical & Sutures, to be analyzed shall be given in

Annexure VII.

1. The Bidder should quote the rates for complete analysis of each product. Name of test(s) to be performed, methodology to be used and number of samples required for each test should be mentioned. However, wherever rates for individual test have been demanded, they should be furnished accordingly in BOQ. Wherever the rates have been quoted for the test prescribed but their name & methodology for testing are not stated, such lab shall be considered as non-responsive for testing for such item.
2. L1 shall be considered on total rate for the complete analysis of each product inclusive of all taxes, levies etc.
3. The rates quoted and accepted will be binding on the Bidder for the stipulated period of 24 months from the date of execution of contract which may be extended for a further period of 03 months with mutual consent of JKMSCL and the firm/ lab and on no account any revision in rates shall be entertained till the completion of the contract period.
4. The laboratory shall not be permitted to outsource any test to other laboratory/ laboratories.
5. JKMSCL shall have the right to cause the laboratory to be inspected by the members of its technical committee before opening of price bid and subsequently as and when considered appropriate and based on the finding, the Bidder may be disqualified or de-empanelled, as the case may be.
6. If deem fit, in the interest of testing, JKMSCL shall have the right to get the molecules/drugs tested from any other empanelled labs of JKMSCL on the approved rates, subject to availability of testing facility and infrastructure.
7. Jammu and Kashmir Medical Supplies Corporation Limited will inform the L-1 rate to the Laboratories who qualify for price bid opening, through JKMSCL website or email. The willing bidders (Laboratories) like (L-2 or L-3) may inform in writing their consents to match with the L-1 rate for the specific item of Drugs /Medicines or any other quoted by them and the bidders who agree to match L-1 rate will be considered as matched L-1. However, the laboratories on matched L1 rates cannot claim for business on matched rates and it will be the sole discretion of the JKMSCL to allot samples on matched L1 rates or not.

8. ACCEPTANCE / REJECTION OF BID:-

1. The Bid evaluation committee formed by Jammu and Kashmir Medical Supplies Corporation Limited will evaluate the Bid with reference to various criteria.
2. The Managing Director, Jammu and Kashmir Medical Supplies Corporation Limited reserves the right to accept or reject any BID for any one or more of the items Bid for, without assigning any reason.

9. AGREEMENT:

1. The period of agreement with empanelled laboratories shall remain valid for a period of 24 months from the date of execution of contract. This may be extended for a further period of three months with mutual consent.
2. All Bidders who qualify for empanelment shall have to execute an agreement on a non-judicial stamp paper of value Rs.100/- (Stamp duty to be paid by the Bidder), in favour of Managing Director, Jammu and Kashmir Medical Supplies Corporation within 15 days from the date of receipt of the intimation which shall be uploaded on www.jktenders.gov.in. The form of agreement shall be issued by JKMSCL.
3. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit there on or any part thereof to any person or persons whatsoever.
4. All notices or communication relating to, or arising out of this tender document or any of the terms thereof shall be considered duly served on or

given to the Bidder if delivered to him or left at the premises, places of business or abode.

10. PERFORMANCE SECURITY:-

1. The successful Bidders shall be required to pay a security deposit of Rs. 50,000/- in the form of demand draft only drawn on any of the scheduled banks in favour of Jammu and Kashmir Medical Supplies Corporation Ltd payable at Jammu atleast three days prior to the execution of the agreement. Performance security will be refunded three months after expiry of rate contract subject to successful completion of services.

11. COMPLETE ANALYSIS & REPORTING CONDITIONS:-

- (a) On empanelment and entrustment of the job, the Analytical Laboratory should furnish the test reports within:
 - 10 days from the receipt of the sample in case of non – sterile products.
 - 21 days from the receipt of the sample of Drugs, Medicines, surgical & sutures requiring test for sterility.
- b) All the tests prescribed under IP/USP.BP Drugs & Cosmetics Act/BIS etc., (as the case may be) should be carried out for each and every sample. The results obtained in the test should be mentioned in numerical value (wherever possible). However this condition will not apply when only specific testing is called for/desired on any particular sample.
- c) “COMPLIES” or “PASSES” in the result column of the report shall be treated as incomplete report, if the result has some numerical value.
- d) Every test report must have remarks either as “Standard Quality” or “Not of Standard Quality”. Any ambiguity/cutting in reports shall not be accepted (clear mention of “standard quality or not of standard quality” should be stated in bold letters and crossing/cutting shall not be accepted). NSQ report should be submitted in red coloured paper rather than writing red colour.
- e) Reports should be clearly legible in printed form on A4 size (8.27” X 11.69”) paper of good quality.
- f) Report should be issued on form 39 of Drugs and Cosmetic Act, 1945 and should have:-

S. no. , Name of drug sample, Code no., Batch no., Mfg. date, Exp. date, Description of tests, Protocol of test specified & applied, Findings & Results obtained and should be signed by person-in-charge of testing. The final results and reason for failure, in case of Not of Standard Quality Reports, should be highlighted in pink / red, rather the whole report should be printed on red paper.
- g) Reports should be attached along with Spectra / Chromatography data sheets, if applicable along with the report without fail.
- (b) All test reports of each batch of sample should be submitted to the JKMSCL in triplicate. However, all results should be communicated immediately to the I/c Quality Control (Q.C.) through phone / E-mail and the report in original should be sent along with protocol within seven days of such intimation/communication.
- (c) If in any circumstances (like break down of instrument, non-availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for a sample, firm shall have to communicate to JKMSCL within 24 hours of receipt of sample through phone and e-mail and firm shall have to return the sample to the I/c Quality Control Cell, Jammu and Kashmir Medical Supplies Corporation after taking necessary telephonic or electronic consent. In case of inability of laboratory to undertake the test, a penalty of

25% of testing charges applicable plus handling/ courier charges borne by JKMSCL if any shall be recovered.

- (d) If placebo or standard test procedure for any product is required, the same should be demanded within 48 hours from date of receipt of sample. Period lapsed/ taken in providing placebo or standard testing procedure will be condoned from prescribed time limit for that sample.
- (e) If any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the I/c Quality Control cell, by phone or E-mail.
- (f) The Managing Director, Jammu and Kashmir Medical Supplies Corporation Ltd or his / her authorized representative(s) has / have the right to inspect the laboratories of the bidders who have submitted BIDs, before taking any decision regarding empanelment. Similarly, the Managing Director, Jammu and Kashmir Medical Supplies Corporation Ltd or his/ her authorized representatives may also inspect any empanelled laboratory, at any point of time during the agreement / contract period and terminate / cancel its empanelment or any orders issued to the laboratory, and not entrust any further testing job to the laboratory based on facts brought out during such inspections.
- (g) It shall be the sole discretion of JKMSCL to allot the samples to any of the empanelled laboratories in case when there is more than one laboratory is approved for a specific item.

12. EXTENSION IN TESTING PERIOD:-

If, at any time during the currency of the contract, the laboratory has, in the opinion of the JKMSCL, delayed in submitting any test report, by the reasons of any riots, mutinies, wars, fire, storm, earthquakes, tempest or other exceptional cause (force majeure), the time for submission of test report may be extended by the JKMSCL purely at its discretion for such period as may be considered reasonable subject to receipt of specific written request by the laboratory with in 48 hrs of occurrence of such an event. No further representation from the laboratory will be entertained on this account.

13. PAYMENT PROVISIONS:-

1. No advance payment towards any analysis shall be made to the empanelled bidder.
2. No payment shall be made for the incomplete analysis or incomplete report.
3. Payments towards the analysis of Drugs, Medicines, Surgical & Sutures will be made as per approved rate inclusive of all taxes, levies etc.

14. PENALTIES:-

1. If the successful Bidder fails to pay the Security deposit and / or to execute the agreement within the time specified or withdraws the BID after intimation of the acceptance of the BID by JKMSCL, the empanelment will be cancelled and the Earnest Money Deposit deposited by the Bidder shall stand forfeited in favour of the Jammu and Kashmir Medical Supplies Corporation Ltd. Such Bidder(s) will also be liable for all damages sustained by the Jammu and Kashmir Medical Supplies Corporation Ltd. to breach of BID conditions. Such damages shall be assessed by the Managing Director, Jammu and Kashmir Medical Supplies Corporation whose decision shall be final.

2. Non performance of the contract or non – adherence to any empanelment condition(s) will disqualify the laboratory from participation from future BIDs for the period of 01 to 05 years as decided by JKMSCL apart from forfeiture of Performance security/ Security Deposit.
3. If it is revealed that the approved analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Jammu and Kashmir Medical Supplies Corporation the analytical laboratory will be debarred for a period not less than 05 years by JKMSCL. The bidders shall also be liable for action under criminal law and the matter will be notified to the concerned Director / Controller – Drugs & Food Control Organization for suitable action against the Laboratories.
4. Omission of any prescribed test will be viewed seriously and shall invite action against the laboratory as deemed fit by JKMSCL, which might range from forfeiting of Performance security to debarring of Laboratory for a period of 02 to 05 years.
5. In case analysis report furnished by the successful bidder lab proves to wrong/fraudulent, or contradictory by an appellant Lab, the successful bidder lab shall be liable to be penalized by forfeiture of performance security or debarring initially for a period, not less than 02 year (or both as deemed fit by TIA).
6. In case Analytical Laboratory fails to furnish the report within the prescribed testing period, the liquidated damages shall be recovered on the basis of following percentage:-
 - a) Delay in furnishing the report within the prescribed testing period with liquidated damages the Penalty shall be imposed @ 0.25% per day for everyday of delay subject to maximum 10%. Rest of Terms & Conditions shall remain same as per SPP.
 - b) Penalty shall not be imposed if a claim with regard to submission of report is complete in all respects is not cleared by JKMSCL within a period of 60 days.
 - (i) Fraction of a day in reckoning the period of delay in furnishing test reports shall be eliminated if it is less than half a day.
 - (ii) The maximum amount of agreed liquidated damage shall be 10%.
 - (iii) Total Penalty period shall be up to 60 days from the last date of providing test report, after which it shall be deemed as unexecuted furnishing of test report and shall attract penalty @20%.
 - (iv) The period for submission of report may be extended with or without liquidated damages. If the delay in the test report is on account of hindrances beyond the control of the Bidder/Lab, the extension in delivery period may be granted without Liquidated Damage.

15. CORRECTION OF ARITHMETIC ERRORS:-

Provided that a financial bid is substantially responsive, the procuring entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

- (a) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;
- (b) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.

- (c) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above. If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

16. Power of acceptance, rejection and withdrawal of the tender:

- a. The power for final acceptance of the tender would entirely vest with the Managing Director, JKMSCL, who reserves the right to accept and reject any or all tender without assigning any reason whatsoever. There is no obligation on part of the Managing Director / GM (TIA) to enter into any correspondence with unsuccessful bidders. After acceptance of the tender by Managing Director, JKMSCL, the bidder shall not have the right to withdraw the tender or claim higher price.
- b. Tender with incomplete information is liable for rejection.

17. SMALL GRIEVANCE

Small grievances regarding interpretation of any clause of the Contract / Agreement executed between the parties, shall be referred to Managing Director, JKMSCL for its clarification.

18. ARBITRATION

18.1 Governing Law: This NIT shall be governed by and construed in accordance with the laws of the State of Jammu and Kashmir and the laws of India as applicable to the State of Jammu and Kashmir.

18.2 Amicable Settlement: Either party is entitled to raise any claim, dispute or difference of whatever nature arising under out of or in connection with the NIT including its existence or validity or termination (collectively "dispute") by giving a written notice to the other party, which shall contain

- i. a description of the dispute
- ii. the ground for such dispute
- iii. all written material in support of its claim

The other party shall, within thirty days of issuance of dispute notice issued under para 18.2.1, furnish:

- I. Counter claim and defenses, if any, regarding the dispute; and
- II. All written material in support of its defenses and counter claim.
- III. Within thirty days of issuance of notice by any party pursuant to para 18.2.1 or para

18.2. Both the parties to the dispute shall meet to settle such dispute amicably. If the parties fail to resolve the dispute amicably within thirty days of the receipt of the notice referred to in the above para the dispute shall be referred to Managing Director, JKMSCL, J&K for its reference to arbitration.

18.3 Dispute Resolution: Besides, as referred above in para 18.2.3 may also include any dispute arising out of contract with regard to the interpretation, meaning and breach of the terms of the contract, the matter shall be referred to the Managing Director, JKMSCL, J&K who will appoint his senior most officer as sole Arbitrator of the dispute, will not be related to this contract and whose decision shall be final and binding on both the parties. The Arbitrator

proceedings shall be governed by the J&K Arbitration and Conciliation Act, 1997. The venue of the Arbitration shall be in the State of Jammu and Kashmir.

19. COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:

Any person participating in a procurement process shall-

- a. Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;
- b. Not misrepresent or omit or misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;
- c. Not indulge in any collusion, Bid rigging or any-competitive behavior to impair the transparency, fairness and progress of the procurement process;
- d. Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;
- e. Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;
- f. Not obstruct any investigation or audit of a procurement process;
- g. Disclose conflict of interest, if any; and
- h. Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

20. CONFLICT OF INTEREST:-

The Bidder participating in a bidding process must not have a Conflict of Interest. A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations

- A Bidder shall be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:
- a. Have controlling partners/shareholders in common; or
 - b. The bidder participating for empanelment of lab is also a manufacturer of AYUSH/Allopathic medicine for which it is seeking empanelment, supplying directly or indirectly to the UT of J&K.
 - c. Receive or have received any direct or indirect subsidy from any of them; or
 - d. Have the same legal representative for purposes of the Bid; or
 - e. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or
 - f. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or

- g. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or
- h. Bidder or any of its affiliates has been hired (or is proposed to be hired by the Procuring Entity as engineer-in charge/ consultant for the contract.

21. Dispute Resolution:

- i) In case of any dispute, the decision of Managing Director, JKMSCL shall be final and binding.
- ii) In case the parties are aggrieved with the decision of Managing Director, he / she / they may refer the dispute for arbitration for which the arbitrator shall be appointed with the mutual consent of both the parties. The arbitration proceedings shall be governed by J&K Arbitration & Reconciliation Act.
- iii) Any legal dispute shall be within the jurisdiction of Hon'ble High Court of Jammu/ Srinagar (J&K).

Note: Any condition(s) which may be left out in this tender document, the same condition(s) shall also constitute the part of this tender document as per its mention in SPP of JKMSCL.

General Manager
J&K Medical Supplies Corporation Ltd

Annexure -C

S.No	Item Name	Item Code
1	Liquid Isoflurane IP/USP250ml Bottle	4
2	Inj. Vecuronium Bromide 10mg (1mg/ml) IP	34
3	Glycopyrrolate 0.5mg + Neostigmine Methylsulphate 2.5mg Inj. 5ml	55
4	Inj. Valethamate Bromide 8mg/ML, 1ml Amp [61]	61
5	Pethidine Hcl Inj. IP50mg/ML.	64
6	Inj. Fentanyl Citrate 50mcg/ML, 2ml Amp [67]	67
7	Fentanyl Citrate Injection I.P 50mcg/ml	67A
8	Pentazocine Inj. IP30 Mg/ML, 1ml Amp	68
9	Aceclofenac + Paracetamol Tab.100mg + 325mg	70
10	Diclofenac Sodium (SR) Tab. IP100 Mg	82
11	Ibuprofen And Paracetamol Tab. IP 400mg + 325mg	84
12	Paracetamol Injection IP 150 mg/ml	93
13	Betamethasone Sodium PhosphateInj. IP 4mg/ML, 1ml Vial	109
14	Prednisolone Tab. IP 20mg	121
15	Inj. Adrenaline 1 Mg/ML, 1ml Amp [123]	123
16	PhenylephrineHydrochloride Injection IP 10mg/ml	134
17	Phenylephrine, chlorpheniramine maleate, Paracetamol, Syrup 2.5mg +1mg +125mg/ 5ml	139
18	Cetirizine, Phenylephrine and Paracetamol Tab. 5 Mg+ 10 Mg +325 Mg	140
19	Phenobarbitone Inj. IP200 Mg/ML	153
20	Inj. Gentamycin 80mg/2ml, Per 2ml Amp [169]	169
21	Amoxicillin And Clavulanic Acid Syp. IP 200mg + 28.5mg/ 5 ML, 30ml	184
22	Cloxacillin Cap. IP500mg	195
23	Erythromycin Stearate Tab. IP 250 Mg	239
24	Inj. Chloroquine Phosphate 40mg/ML IP	301
25	Cyclophosphamide Inj. IP 200 Mg	327
26	Cyclophosphamide Inj. IP 500 Mg	328
27	Inj. Etoposide 100 Mg/5ml IP	335
28	Inj. Ifosfamide 1gm IP	358
29	Inj. Heparin Sodium 5000 Iu/5ml, 5ml Vial [373]	373
30	Inj. Rh - Erythropoetin 10000iu [402]	402
31	Inj. Amino Acid, 250 ML Bottle [406]	406
32	Tab. Aspirin Delayed Release (Entericcoated) 75mg [420]	420
33	Tab. Methyldopa 250mg [445]	445
34	Digoxin Inj. IP 0.25 Mg/ML	465
35	Glycerin 100 ML Pack IP	497
36	Solution Hydrogen Peroxide 6%w/v	520
37	Silver Sulphadiazine Cream 1% W/W, 50gram Tube [528]	528
38	Surgical Spirit IP/BP500 ML Bottle	531

S.No	Item Name	Item Code
39	Surgical Spirit IP/BP 100 Ml Bottle	532
40	Norethisterone 5 mg IP	621
41	Tab. Carbimazole 5 Mg IP	624
42	Inj. Snake Venom Anti Serum Lypholized (Polyvalent Anti Snake Venum) 10ml , 10ml Vial [641]	641
43	Brimonidine Tartrate And Timolol Eye Drops 0.15%+0.5% , 5ml Vial	656
44	Atropine Sulphate OphthalmicSolutionBP 1% , 5ml Vial	662
45	Pilocarpine Eye Drops 2% W/V	664
46	Eye Drops Chloramphenicol 0.5% IP	667
47	Carboxymethyl Cellulose Sodium Lubricant Eye Drops IP0.50%, 10ml Vial	677
48	Sodium Carboxymethyl Cellulose Eye Drops I.P 0.5% W/V	677A
49	Inj. Isoxsuprine 5 Mg/Ml, 2ml Amp [686]	686
50	Tab. Methyl Ergometrine 0.125mg [689]	689
51	Inj. Chlorpromazine25 Mg/MlIP	702
52	Tab. Haloperidol 5mg IP	703
53	Inj. Buprenorphine 0.3mg/ml	752
54	Aminophylline Inj. IP 25mg/Ml, 10ml Amp	754
55	Inhaler Budesonide(A)+ Formoterol (B) Inhalation 160mcg (A) + 4.5 mcg (B)/dose	755
56	Budesonide Inhalation Suspension 0.25mg/2ml	756
57	Salbutamol InhalationIP 100 mcg/ dose	763
58	Iron And Folic Acid [Ferrous Fumerateeq To Elementaliron 100mg, Folic Acid 500mcg Pe R5ml]Syp.	802
59	Tab. Pyridoxine 40 Mg Hcl IP	809
60	Inj. Vitamin B-Complex Nfi , Vial [816]	816
61	Inj. Human Albumin 20% 100ml Bottle/Bag [860]	860
62	Isolyte PInj.500ml Bottle	864
63	Intra Lipid Injection 10%.	869
64	IrinotecanInj. IP/USP100mg/5ml	899
65	Tab. Clotrimazole Pessaries 200 Mg [920]	920
66	Recombinant Third Generation Factor Viii (250 Iu) As Per Wfh Standard Guidelines, Vial [949]	949
67	Inj. Succinyl Choline 50mg/Ml, 10 Ml Vial [955]	955
68	Inj. Butorphanol 2mg/ml	968
69	Warfarin (Sodium) Tab. IP 2mg	1035
70	Inj. Diltiazem 5mg/Ml, 5 Ml Single Dose Vial [1048]	1048
71	Inj. Enalapril 1.25mg/ml	1049
72	Inj. Vasopressin 20 Iu/Ml , 1ml Amp [1065]	1065
73	Polymyxin B Sulphate + Neomycin Sulphate + Zn Bacitracin 5000iu+3400 Iu+400 Iu/ Gm Oint.	1075

S.No	Item Name	Item Code
74	Inj. Rocuronium Bromide 10mg/ml	1116
75	Inj. Ritodrine 10mg/ml	1144
76	Inj. Olanzapine 10mg/vial	1150
77	Inj. Zuclopenthixol Long action 200mg/ml	1154
78	Tab. Clozapine 100mg	1156
79	Tab. Oxazepam 15mg	1162
80	Tab. Clonazepam 0.5mg	1164
81	Tab. Bupropion 300mg Modified Release	1166
82	Tab. Buprenorphine (Sub Lingual) 0.2mg	1173
83	Inj. Methylcobalamine 1500mcg/2ml, 2 MI Amp.	1191
84	Cap. Didanosine Delayed Release 250mg	1205
85	Cap. Didanosine Delayed Release 400mg	1206
86	Cap. Stavudine 30mg	1210
87	Cap. Stavudine 40mg	1211
88	Tab. Zidovudine 100mg	1212
89	Inj. Palonosetron 0.25mg/5ml Vial	1226
90	Tab. Palonosetron 0.5mg	1227
91	Glycerol Oral Liquid, 500 MI Bottle	1250
92	Inj. Ketamine Hydrochloride 10mg/ml, 5ml Prefilled syringe	1265
93	Lignocaine Hydrochloride Topical cream 3% w/v	1269
94	Diclofenac Transdermal Patch 200mg, 75sq. cm	1271
95	Suspension Chlorpheniramine Maleate (Pediatric Only) 2 Mg/5ml, 30 MI Bottle	1280
96	Inj. Flumazenil 0.1 mg/ml, 5ml vial	1286
97	Linezolid 100mg/5ml For Oral Suspension With 25ml Wfr, 30ml Bottle	1307
98	Inj. Metoprolol 1mg/MI	1317
99	Formaldehyde Solution 37%-40% w/v	1341
100	Inj. Anti D 150mcg/Vial, Per Vial	1358
101	Inj. Physostigmine 1mg/ml	1362
102	Inj. Mivacurium Chloride 2mg/ml	1363
103	Inj. Balanced Salt Solution Sterile Irrigating Solution, Per 500ml Bottle	1365
104	Atropine Sulphate Eye Ointment 1% W/W, 5gm, Each 5gm Tube	1370
105	Capsule Glycopyrronium powder for inhalation 50mcg	1398
106	Acetylcysteine Solution 200mg/MI	1399
107	Inj. Sodium Stibogluconate 100mg/ml	1433
108	Tab. Melphalan 2mg [1438]	1438
109	Inj. Mitomycin-C 2mg, single dose vial	1442
110	Barium Sulfate Suspension 100% W/V,	1451

S.No	Item Name	Item Code
111	Instrument Disinfectant (Ortho Phthalaldehyde 0.55%) (Each 5 Litre Pack), Per 1 Litre Pack	1453
112	Injection Ropivacaine 0.5%, 5mg/ML, 150mg/30ml, Per 30ml Vial	1465
113	Tab. Favipiravir 200 Mg	1469
114	Injection Tinidazole 2mg/ML, 400ml Bottle	1477
115	Injection Factor-Viii Inhibitor Bypassing Agent (Feiba) 500iu, Per Vial	1478
116	Injection Labetolol Hydrochloride 5mg/ML, 20ml Multi Dose Vial	1480
117	Inj. Immunoglobulin 10% , 100ml Bottle	1485
118	Injection Flupentixol deconate 20 mg/ml, 1ml ampoule	1491
119	Inj. Amino Acid 10% W/V,100ml Bottle	1494
120	Injection Vinblastine 1mg/ML, Per 10ml Vial	1499
121	Tablet Erlotinib 150mg	1500
122	Injection Fluorescein 100mg/ml	1508
123	Injection Methotrexate 25mg/ml	1512
124	Injection Actinomycin-D 500mcg/0.5mg/USP	1537
125	Injection Iohexol 350mg I/ML, 100ml Vial	1539
126	Inj. Recuronium 10mg/ml	1605
127	Inj. Decarbazine 500 mg	1608
128	Inj. Planosterone 0.25mg/5ml	1609
129	Inj. Haloperidol 5mg	1612
130	Inj. Lorazepam 4mg/ML, Per Vial	1613
131	Tab. Clobazam 10mg, Per Tab	1614
132	Tab. Aripirazole 10mg	1615
133	Tab. Metformin Hydrochloride Extended- Release 850mg	1616
134	Inj. Phenytoin Sodium 50 Mg/ML, 5ml Amp	1620
135	Inj. Vitamin K1 1mg/0.5ml Single Dose , 0.5ml Amp	1624
136	Tab. Calcium 500mg (Calcium Carbonate 1250 Eq To Calcium 500mg + Vitamin D3 250 I.U.)	1625
137	Tab. Domperidone 10mg.	1627
138	Syp. Domperidom 1mg/ML ,Per Bottle Of 30ml	1629
139	Tab. Methyl Prednisolone 8mg	1633
140	Tab. Methyl Prednisolone 16mg	1634
141	Inj. Liposomal Amphotericin B 50mg, Per Vial	1646
142	Nonacog Beta Pegol 500iu/Vial	1649
143	Sachet Dextrose Monohydrate Powder, 75grams/Sachet, Per Sachet	1650
144	Nonacog Beta Pegol 2000iu/Vial	1651
145	Turoctocog Alfa Pegol (R-Dna Origin) 500iu/Vial	1652
146	Turoctocog Alfa Pegol (R-Dna Origin) 1000iu/Vial	1653
147	Turoctocog Alfa Pegol (R-Dna Origin) 1500iu/Vial	1654
148	Turoctocog Alfa Pegol (R-Dna Origin) 2000iu/Vial	1655

S.No	Item Name	Item Code
149	Rurioctacog Alfa Pegol Factor Viii (Pegylated) 500 Iu/Vial, Per Vial	1656
150	Tab. Entecavir 0.5mg	1657
151	Tab. Entecavir 1mg	1658
152	Inj. Somatropin Biosynthetic-R-Dna Origin (Hgh), Pfs, 15mg/1.5ml , Per Pfs	1659
153	Biphasic Insulin Aspart 100u/MI (Mixture Of Insulin Aspart (30%) + Insulin Aspart Protamine (70%), 3ml Penfill	1660
154	Insulin Aspart 100u/MI, 3ml Penfill	1661
155	Insulin Degludec 100u/MI, 3ml Penfill	1662
156	Insulin Degludec Aspart (70% Degludec And 30% Aspart) 100u/MI, 3ml Penfill	1663
157	Tab. Semaglutide 3mg	1664
158	Tab. Semaglutide 7mg	1665
159	Tab. Semaglutide 14mg	1666
160	Tab. Dolutagravir 50mg.	1667
161	Tab. Tenofovir 300mg+Lamivudine 300mg	1668
162	Inj. Denosumab 120mg/1.7ml Vial	1669
163	Inj. Trastuzumab 440mg, Per Each Pack	1670
164	Inj. Trastuzumab 150mg, Per Each Pack	1671
165	Inj. Bortezomib 2mg/Vial, Per Vial	1672
166	Inj. Pneumococcalm Polysacheride Vaccine 23(Ppsv-23), 25mcg/0.5ml Pfs	1673
167	Inj. Omalizumb 150mg/1ml Pfs	1674
168	Topical Heparin Solution 1000 Iu/MI (With Qps Technology), Per 5ml Bottle	1675
169	Spray Diclofenac Diethylamide 4.64% W/V (With Qps Technology), 30ml Bottle	1676
170	Nasal Spary Methyl Cobalamine, 250mcg/Spray, 2.3ml Bottle(46 Sprays), Per 2.3ml Bottle	1677
171	Inj. Goserelin Acetate 3.6mg Pfs	1678
172	Inj. Goserelin Acetate 10.8mg Pfs	1679
173	Tab. Olaparib 150mg Film Coated	1680
174	Tab. Olaparib 100mg Film Coated	1681
175	Tab. Osimertinib 80mg	1682
176	Inj. Durvalumab 120mg/2.4ml	1683
177	Inj. Durvalumab 500mg/10ml	1684
178	Tab. Methadone 10mg	1685
179	Cream Framycetin 1% W/V, 100gram Tube	1686
180	Inj. Pneumococcal Polysacheride Conjugate Vaccine 13-Valent, 0.5ml Pfs	1687

S.No	Item Name	Item Code
181	Inj. Iopromide Injection 77% W/V, 370 Mg I/MI, Per 100ml Bottle	1688
182	Inj. Gadobutrol 1.0 Mmol/MI, Each 5ml Vial	1689
183	Inj. Benralizumb 30mg/MI, Per 1ml Pfs	1690
184	Tab. Abemaciclib 150mg	1691
185	Tab. Abemaciclib 200mg	1692
186	Inj. Ramucirumab 100mg, 10ml Vial	1693
187	Inj. Ramucirumab 500mg, 50ml Vial	1694
188	Inj. Docaravimub And Miromavimab 1500iu/2.5ml Vial (Anti-Rabies Monoclonal Antibody), Per 2.5ml Vial	1695
189	Tab. Buprenorphine 2mg + Naloxone 0.5mg	1696
190	Tab. Tapentadol 50mg	1697
191	Tab. Tapentadol 100mg	1698
192	Tab. Clonidine 0.1mg	1699
193	Tab. Ibuprofen 400mg+ Chlorzoxazone 250mg	1700
194	Tab. Loperamide 2 Mg	1701
195	Tab. Lorazepam 2mg	1702
196	Inj. Lorazepam 2mg/MI, 1ml Vial/Ampoule	1703
197	Tab. Baclofen 20mg	1704
198	Tab. Tolperisone 150mg	1705
199	Tab. Gabapentin 100mg	1706
200	Tab. Flupirtine Maleate 400mg	1707
201	Tab. N-Acetylcysteine 600mg	1708
202	Tab. Zolpidem Tartrate 10mg	1709
203	Cap. Rifampicin 600mg	1710
204	Cap. Rifampicin 300mg	1711
205	Tab. Acamprosate 333 Mg	1712
206	Tab. Buprenorphine 0.4mg (Sublingual)	1714
207	Inj. Paclitaxel 100mg/16.67ml Vial, (6mg/MI), Per Vial	1716
208	Inj. Epirubicin 100mg/Vial	1717
209	Inj. Cyclophosphamide 500mg/Vial, Per Vial	1718
210	Inj. BCG 40mg/ml vial	1721
211	Inj. Pegfilgrastim 6mg/0.6ml Pfs, Per 0.6ml Pfs	1722
212	Inj. Fluorouracil 500mg, Per 10 MI Ampoule/Vial	1723
213	Spray BTI (Bacillus Thuringiensis Israelensis)	1724
214	Human Factor Viii With Vwf Concentrate 2.5ml Vial, With 90-250 Iu/MI Of Vwf	1725
215	Human Coagulation Factor-X 250-IU/vial.	1726
216	Inj. Risperidone long acting 25mg/2ml	1735
217	Oxygen Gas for Inhalation Can with Mask	1740
218	Ibuprofen Oral Liquid 100mg/5ml, 50 MI Bottle	1742

S.No	Item Name	Item Code
219	Prednisolone Oral liquid 5 mg/5 ml	1743
220	Hydroxyzine oral syrup 10mg/ 5ml	1744
221	Activated Charcoal	1745
222	Diazepam Tablet 10mg	1746
223	Diazepam rectal suppository 2.5mg	1747
224	Ciprofloxacin Oral liquid 250 mg/5ml	1748
225	Cefixime Oral Liquid 100 Mg/5 ML, 30 ML Bottle	1749
226	Tab. Co-Trimoxazole (Sulphamethoxazol 80 Mg + Trimethoprim 400 Mg)	1750
227	Doxycycline Dry Syrup 50mg/5 ml	1751
228	Norfloxacin oral liquid	1752
229	Injection Cefazolin 500 Mg, Per Vial	1753
230	Clotrimazole Drops 1%, 10 ML Bottle	1754
231	Clotrimazole Cream 1%, 15gm Tube	1755
232	Tablet Deriphylline Sr 300mg	1756
233	Tablet Levodops 100 M + Carbidopa 10mg	1757
234	Tablet Ferrous Sulphate 20mg + Folic Acid 100mcg	1758
235	Tablet Diltiazem 60mg	1759
236	Tablet Isosorbide Dinitrate Tablet 5mg (Sublingual)	1760
237	Tab Chlorthalidone 6.25 Mg	1761
238	Betamethasone Cream 0.1%, 15gm Tube	1762
239	Benzyl Benzoate IP 25% W/W 100ml bottle	1763
240	Potassium Permanganate 0.1%	1764
241	Chlorhexidine Solution 5% (concentrate for dilution)	1765
242	Methylrosanilinium chloride (Gentian Violet)	1766
243	Tablet Furosemide 40mg	1767
244	Wax Solvent Ear Drops: Benzocaine, Chlorbutol, Paradichlorobenzene, Turpentine Oil, 10 ML Bottle	1768
245	Combo ear drop-Chloramphenicol 5% w/v +clotrimazole 1%+Lignocaine hydrochloride 2%	1769
246	Ondansetron Oral Liquid 2 Mg/5ml, 30 ML Bottle	1770
247	Tablet Hyoscine Butyl Bromide 10mg	1771
248	Ispaghula Granules/ Husk/Powder	1772
249	Tablet Drotavarin 500 mg	1773
250	Bisacodyl Suppository 5 mg	1774
251	Magnesium Hydroxide liquid 7.75%, 400 mg/ 5 ml	1775
252	Sucralfate Oral Liquid 1 Mg/ML, 100 ML Bottle	1776
253	Tablet Hyoscine butylbromide 500 mg	1777
254	Tablet Glibenclamide 2.5 Mg	1778
255	Glucose Packet 75 mg for OGTT Test	1779

S.No	Item Name	Item Code
256	Tablet Levothyroxine 100 Mcg	1780
257	Montelukast Syrup 4 ml	1781
258	Syrup Bromhexine Hydrochloride 2mg	1782
259	Syrup Phenniramine Maleate 15mg/5ml	1783
260	Pediatric solution like isolyte P, N/2 & N/S	1784
261	Potassium Chloride Oral Liquid 500mg/5ml, 100ml Bottle	1785
262	Tablet Cholecalciferol 60,000 Iu	1786
263	Tablet Pyridoxine 100 Mg	1787
264	Lignocaine Eye drop 4%	1788
265	Sodium Cromoplycate 2% eye drop	1789
266	Tablet Ethinylestradiol 0.03 mg + Levanorgestrel 0.15 mg	1790
267	Non- hormonal Ormeloxifene (30 mg Tablet)	1792
268	Emergency Contraceptive Pill Levonorgestrel 1.5mg, Per Tab [1793]	1793
269	Injection Medroxyprogesterone Acetate 150mg	1794
270	Spray Pyrethrum 2% Extract 2% E.C.	1795
271	Spray Temephos 50%	1796
272	Tab. Chloroquine 200mg	1797
273	Spray Cyphenothrin 5%	1798
274	Phytomenadione (Vitamin K1) Inj. I.P 10 mg/ ml	1799
275	Chlorothalidone 6.25 mg IP tablets	1800
276	Mannitol Injection I.P10 % W/V	1801
277	MetoclopramideSuspensionI.P 5 mg/ 5 ml	1802
278	MetoclopramideInjection I.P 5 mg/ ml	1803
279	OndansetronOral Solution I.P 2mg/5ml,	1804
280	Montelukast Sodium Syrup I.P 4 mg/ 5 ml	1805
281	Medroxyprogesterone AcetateInjectionI.P 150 mg/ml	1807
282	Acetazolamide Injection USP 500mg/vial	1808
283	PlazomicinInjection (50mg/ml) 500 mg/ 10 ml vial	1809
284	Lyophilized Ertapenem Injection 1 gm	1810
285	Ceftazidime(2gm)&Avibactam0.5 gmInjection	1811
286	Meropenam&Vaborbactam Injection 1 gm each	1812
287	Ceftolozane&Tazobactam Injection 1.5gm per vial	1813
288	Calcitonin(Salmon) InjectionI.P 100 IU	1814
289	Calcitonin (Salmon) Nasal Spray I.P 3.7 ml Solution/Bottle	1815
290	FentanylTransdermalPatch 50 mcg/hr	1816
291	Fentanyl TransdermalPatch100 mcg/hr	1817
292	BuprenorphineTransdermalPatch5mcg	1818
293	Buprenorphine TransdermalPatch10 mcg	1819
294	Buprenorphine TransdermalPatch20 mcg	1820
295	GlucagonInjection USP 1mg	1821

S.No	Item Name	Item Code
296	Tirofiban Hydrochloride Injection 5mg/100ml	1822
297	Ribavirin Cap. USP 200mg	1823
298	Desmopressin Acetate Tab. BP 0.1mg	1824
299	Desmopressin Nasal Spray I.P 0.01% W/V	1825
300	Nimodipine Injection BP 10 mg/ 50 ml	1826
301	Nimodipine Tab I.P 30mg	1827
302	Romiplostim Injection 125mcg	1828
303	Daratumumab Injection 100mg/ 5 ml	1829
304	Daratumumab Injection 400mg/ 20 ml	1830
305	Trastuzumab Emtansine Injection 100mg	1831
306	Trastuzumab Emtansine Injection 160mg	1832
307	Paclitaxel Injection I.P 30mg /5ml vial	1833
308	Liposomal Doxorubicin Injection 20mg/ 10 ml	1834
309	Liposomal Doxorubicin Injection 50mg/ 25 ml	1835
310	Bevacizumab Injection 400mg/ 16 ml	1836
311	Bevacizumab Injection 300mg/12 ml	1837
312	Bevacizumab Injection 100mg/4 ml	1838
313	Tagafur + Gimeracil + Oteracil, Cap. 20mg+5.8mg+15.8mg	1839
314	Tagafur + Gimeracil + Oteracil, Cap. 15mg+4.35mg+11.8mg	1840
315	Tagafur/ Uracil Cap. 100mg+ 224mg	1841
316	Rucaparib Tab. 250mg	1842
317	Pertuzumab+ Trastuzumab Injection 600mg+600mg in 10 ml	1843
318	Pertuzumab + Trastuzumab Injection 1200mg / 600mg in 15ml	1844
319	Garenoxacin Tab. 200mg	1845
320	Golimumab Auto Injector 50mg/0.5ml	1846
321	Ustekinumab Infusion Injection 130mg/26ml	1847
322	Ustekinumab Injection 90 mg/ml	1848
323	Netupitant Palonosetron Cap. 300mg + 0.5mg	1849
324	Ibrutinib 140 mg	1851
325	Nimotuzumab Injection 200 mg 50 mg / vial (Pack of 4vials)	1853
326	Amivantamab Injection 350mg/7ml	1854
327	Trastuzumab 375mg (Trastuzumab Lyophilized Powder for concentrate for infusion) Injection	1855
328	Insulin Lisipro (25% Insulin Lisipro & 75% Insulin Lisipro Protamine Suspension) Injection	1856
329	Insulin Lisipro (50% Insulin Lisipro & 50% Insulin Lisipro Protamine Suspension) Injection	1857
330	Insulin Lisipro Injection 100U/ml	1858
331	Secukinumab Injection 150mg/ml	1859
332	Human Fibrinogen Injection BP 1gm	1860

S.No	Item Name	Item Code
333	Human AlbuminInjection IP 5%, 250ml	1861
334	AtezolizumabInjection 1200 mg/ 20 ml	1862
335	ObinutuzumabInjection 1000 mg/ 40 ml	1863
336	AlteplaseInjectionEP 20mg	1864
337	Alteplase InjectionEP 50mg	1865
338	Empagliflozin 25mg Tab.	1866
339	Empagliflozin/Linagliptin 25mg+ 5mg Tab.	1867
340	Cangrelor Injection50mg/vial	1868
341	Two Component Fibrin Sealant with Synthetic Aprotinin 4ml	1869
342	Endoxifen Tab. 8mg	1870
343	Desidustat Tab. 100mg	1871
344	Human Prothrombincomplex Injection IP 250mg	1872
345	Axitinib Tab. 5mg	1873
346	Retepase Injection 18mg	1874
347	Fosnetupitant + PalonosetronInjection 235mg + 0.25mg/vial	1875
348	Rucaparib Tab. 300mg	1876
349	Palbociclib Tab.125mg	1877
350	Cabozantinib Tab. 60mg	1878
351	Pertuzumab Injection 420 mg/ 14 ml	1879
352	Triple Chamber Peripheral parenteral nutrition bag with olive oil	1880
353	Nivolumab Injection 10 mg/ ml, 40mg	1881
354	Nivolumab Injection 10 mg/ml, 100mg	1882
355	Luspatercept Injection 25mg/Vial	1883
356	Luspatercept Injection 75mg/Vial	1884
357	Tenecteplase Injection 20mg	1885
358	Tenecteplase Injection 40mg	1886
359	Ipilimumab Injection 50mg/ 10 ml	1889
360	AvelumabInjection 200mg/10 ml	1890
361	CetuximabInjection 100mg/20ml (5mg/ml)	1891
362	Cetuximab Injection500mg/100ml	1892
363	Darbepoetin Alpha Injection 25mcg	1893
364	Darbepoetin AlphaInjection 40mcg	1894
365	Darbepoetin Alpha Injection60mcg	1895
366	BortezomibInjectionIP 2.5 mg	1896
367	Recombinant FSH Injection 1050IU/1.75 ml	1898
368	Recombinant FSH Injection 450 IU/ 0.75 ml	1899
369	Ixekizumab Injection 80mg /ml	1900
370	Desidustat Tab 25mg	1901
371	Desidustat Tab 50mg	1902

S.No	Item Name	Item Code
372	Hepatitis A Vaccine. (Inj. Freeze Dried live attenuated Hepatitis A Vaccine 0.5 ml/ (Single dose)	1904
373	Inj. Human Papilloma Virus (HPV) Recombinant 0.5 ml vial (single dose) Types: 16 and 18 are mandatory Vaccine covering maximum mentioned strains is desirable 31,33,34,35,39, 45, 51, 52, 56, 58, 59, 66, 68 & 70	1905
374	Meningococcal meningitis Polysaccharide Bivalent (A&C) vaccine Freeze Dried purified Polysaccharide vaccine 0.5 ml vial (single dose)	1906
375	Tagafur Tab/ Cap. 20 mg	1907
376	Gimeracil Tab/ Cap. 5.8 mg	1909
377	SARS COV-2 IgGNucleoprotein (NP) Prefilled Syringe	1913
378	Polymyxin B Injection USP 500000 IU	1914
379	Fulvestrant Injection 250 mg/5 ml	1915
380	L-AlanylL-Glutamine 20% W/VInjection	1916
381	Glutathione 600mgInjection	1917
382	Ketamine Injection IP/USP500 mg/ 10 ml	1918
383	Multiple Electrolytes 500 ml bottle	1919
384	Leuprolide Acetate Injection 22.5mg	1921
385	Leuprolide AcetateInjection 3.75mg	1922
386	Leuprolide Acetate Injection 11.25 mg	1923
387	Sodium Chloride NS I.P 0.9% W/V 3ltr	1924
388	Polyethylene Glycol 118.00g, Potassium Chloride1.484g, Sodium Bicarbonate 3.370g, Sodium Chloride 2.930g and Anhydrous Sodium Sulphate B.P 11.360g , oral solution 137.15g	1925
389	Rituximab Injection 100 mg/ 10 ml	1926
390	Ropivacaine Injection IP 2%	1927
391	CLV Injection	1929
392	Lignocaine Injection 2%	1930
393	Zoledronic Acid Injection IP4 mg	1931
394	Formalin Tab 250 mg	1932
395	Formalin Tab500 mg	1933
396	Formalin Tab1000 mg	1934
397	Metoprolol Tartrate Injection IP 1 mg/ml	1935
398	ClindamycinInjectionIP600 mg	1936
399	Methylprednisolone acetate InjectionIP80 mg/2 ml	1937
400	Povidone Iodine OintmentUSP 5% W/W	1938
401	FramycetinSulphate Ointment I.P 1% W/W30 g	1939
402	Notripyline Tablets IP 10mg	1941
403	Notripyline Tablets IP 25mg	1942
404	Tramadol 37.5mg + PCM 325 mgTab. USP	1943

S.No	Item Name	Item Code
405	Feracrylum Sodium, 3%w/w Gel, 15gm tube	1944
406	Sertaconazole Nitrate 2% W/V lotion30 ml	1945
407	MometasoneFuroate USP 0.1% W/V lotion	1946
408	Diclofenac Sodium, Trypsin, Rutoside Trihydrate, Bromelain Tab	1947
409	Bortezomib Injection IP 2mg	1948
410	Recombinant Tissue PlasminogenActivator injection kit 18 mg	1949
411	Tobramycin Sulphate Inj.IP 80 mg	1950
412	Haemophilus B Conjugate Vaccine 0.5 mlInj	1951
413	Meningococcal Vaccine 0.5 ml 10ug each of (Meningococcal A, C, W, and Y polysaccharides conjugated to approximately 55 µg of tetanus toxoid protein carrier)Inj.	1952
414	Octreotide Acetate Inj. 100mcg/ ml	1953
415	Colistimethate Sodium for Injection IP- 4.5 MIU	1954
416	Pilocarpine Nitrate1 ml eye/per drop 0.5% W/V	1955
417	BCG for Immunotherapy 40 mg IP Freez driedInj.	1956
418	Voriconazole Inj. IP 200 mg	1957
419	Fosfomycin Sodium Inj. 4 g	1958
420	Caftazidime + Avibactam Inj. 2gm & 0.5 gm	1959
421	TriamcinoloneAcetonide Inj. IP40mg/ml, 5ml	1960
422	Nepafenac 0.1% W/V Eye Drops 5ml	1961
423	HydroxyPropylMethylCellulose 2.4 % Ophthalmic Solution. IP 5 ml	1962
424	Sulphur Hexafluoride SF6 Gas 75 ml	1964
425	AbirateroneAcetate Tab. IP 500 MG	1965
426	Aprepitant Cap. IP 125mg/80mg	1966
427	Aprepitant Capsule IP 80 mg	1967
428	Eltrombopag Olamine Tab. 25 mg	1968
429	EltrombopagOlamineTab. 50 mg	1969
430	Etoposide Cap.IP 50 mg	1970
431	Carica Papaya + TinosporaCardifoliaCap. 350 mg/150 mg	1972
432	Sunitinib Malate Capsules 50 mg	1973
433	Diclofenac Sodium + Thiocolchicoside Tab. 50mg + 4 mg	1974
434	Diclofenac Sodium + Thiocolchicoside Tab.50mg + 8 mg	1975
435	Indomethacin IP Cap 50 mg	1976
436	Ibuprofen + Paracetamol Tab IP. 400 mg + 325 mg	1977
437	Levofloxacin Tab IP500 mg	1978
438	Clindamycin IP Cap. 600 mg	1979
439	ParacetamolTab IP 1 gm	1980
440	Diclofenac Tab. IP75 mgProlonged Release	1981
441	Piroxicaminjection IP40mg	1982
442	Methylprednisolone Tab. IP 4 mg	1983

S.No	Item Name	Item Code
443	Deflazacort Tab IP 6mg	1984
444	Glycopyrolate Injection IP0.2 mg/ml	1987
445	HAES 3 sterile infusion	1988
446	ProgesteroneInjectionIP25 mg/ml	1990
447	EnalaprilatInjectionUSP 1.25mg/ml or 2.5 mg/2ml	1991
448	Sodium ValproateInjection IP100 mg/ml	1992
449	Calcium Chloride Injection IP 100mg/ml	1993
450	LevofloxacinInjectionIP 500mg / 100ml	1994
451	Voriconazole Injection IP 200 mg	1995
452	Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg Tab	1996
453	Tranaxemic Acid 500 mg + Mefenamic acid 250 mg Tab	1997
454	Milrinone LactateInjection USP 10 mg/ 10ml	1998
455	Milrinone LactateInjectionUSP 20 mg/20ml	1999
456	Corticotrophin CarboxymethylcelluloseInjection BPC 73 60 IU/ml	2001
457	Regular/Neutral Monocomponent Insulin (Human) 100 IUInj. IP	2004
458	Thiamine Hydrochloride-100mg, Pyridoxine-100mg, Cyanocobalamin-1000mg, Nicotinamide-100 mg, D- Panthenol-50mg, Benzyl Alcohol-2%w/vInj.	2005
459	Alprostadil InjectionI.P 500mcg/ml	2006
460	Sildenafil Inj. IP 10 mg/12.5 ml	2007
461	Iron Syp. Each 5ml Contains Colloidal Iron eq. to elemental Iron 250 mg, Lysine, Folic Acid 500mcg, Vitamin B12 IP5µg	2008
462	LevocarnitineSyp. USP500 mg/ 5 ml	2010
463	DigoxinSyp. IP50 mcg/ ml	2011
464	Thiamine HydrochlorideSyp. 2 mg	2012
465	Medium Chain Triglyceride Syp.	2013
466	FrusemideDropUSP 10mg/ml	2014
467	Oseltamivir Phosphate Oral Syp. IP 12 mg/ml	2015
468	Spirolactone Tab IP 25 mg	2017
469	Spirolactone Tab IP 50 MG	2018
470	Spirolactone Tab IP 100 MG	2019
471	LorlatinibTab. 25mg	2020
472	LorlatinibTab.100 mg	2021
473	Crizotnib Cap. 250 mg	2022
474	Dacomitinib Tab. 30 mg	2023
475	Recombinant Human Epidermal Growth Factor Silver Sulfadiazine &ChlorhexidineGluconate Cream30gm	2024
476	Recombinant Human Epidermal Growth Factor Gel30 gm	2025
477	InotuzumabOzogamicin Injection 1mg/Vial	2026
478	Typhoid VI Conjugate Vaccine IP 0.5 ml	2027

S.No	Item Name	Item Code
479	Human Papilloma Virus (HPV) 9 Valent Vaccine Recombinant 0.5 ml (6, 11, 16, 18, 31, 33, 45,52, 58)	2028
480	Malathion Technical 95% W/W	2029
481	Jaswant Singh Bhattacharjee-I Stain	2030
482	Jaswant Singh Bhattacharjee-II Stain	2031
483	Herpes Zoster Vaccine (Recombinant, Adjuvanted)	2033
484	AntithymocyteGlobulin-Equine 250 mg/5 mlInjection	2034
485	Glargine Insulin I.P 100 IU/ML (r-DNA origin) 3 ml	2035
486	Glargine Insulin I.P 100 IU/ML (r-DNA origin)10 ml	2036
487	Levonadifloxacin Injection800 mg/ 100 ml	2037
488	Sofosbuvir 400 ml and Velpatasvir100mg Tab.	2038
489	Cap 1 billion C.F.U of Lactobacillus Rhamnosus GR-1,Lactobacillus Reuteri RC-14	2039
490	Dexketoprofen 25mg + Paracetamol 325 mg	2040
491	Cholecalciferol IP 1000 IU Each Hard Gelatin Cap contains:Calcium 300mg (In the Form of Calcium Hydroxide And Calcium Oxide Pretreated With Heated Algae)	2041
492	Feracrylum 1% w/v sterile solution	2042
493	Feracrylum Gel 3% W/W	2043
494	Sertaconazole Nitrate B.P 2% W/V	2044
495	Mometasone Furoate Cream 0.1% W/V	2045
496	Paracetamol I.P 650 mg	2046
497	Domperidone I.P 20 Mg	2047
498	Inj. Mepolizumab 100mg	2048
499	Oint. Silver Sulfadiazine (Nanonized) 0.5% w/w + Chlorhexidine Gluconate 0.2% cream	2049
500	Blood Sample Cardiac Troponin T Test Kit	2050
501	Drug C1 Esterase Inhibitor Hereditary ANGIO Edema (HAE)	2051
502	Injection Hepatitis- B Immunoglobulin 100 IUvial/1ml	2052
503	Inj. Diphtheria and Tetanus Vaccine 0.5ml	2053
504	Polymyxin B Sulphate + Neomycin Sulphate + Zn Bacitracin 5000iu+3400 Iu+400 Iu/ Gm Oint. 10gm Tube	2054
505	Inj. Hepatitis- B Immunoglobulin 100 mg/0.5 ml IP	2055
506	Inj. Nanosomal Paclitaxel 100mg Lyophilized	2056
507	Inj. Multivitamin 10 ml	2057
508	Inj. Amino Acid (Infusion), 200 ml	2058
509	Inj. Sugammadex 200mg/2ml	2059
510	Injection Hepatitis- B Immunoglobulin 100 IU vial/0.5ml	2060
511	Inj. Gemcitabine I.P. 1400mg	2061
512	Inj. Nab-paclitaxel 100mg	2062

S.No	Item Name	Item Code
513	Inj. Surfactant Intratracheal Suspension, 3ml	2063
514	Tab. Chloroquine 250mg	11728
515	Tab. Chloroquine 500mg	11729
516	Tab. Abemaciclib 50mg	11733
517	Tab. Abemaciclib 100mg	11734
518	Inj. Ferric Carboxymaltose 1000mg/20ml, 20ml Vial	11736
519	Inj. Desferoxamine 500mg	1037A
520	Tab. Methadone 5 mg	1169A
521	Cap. Leucovorin Calcium 15mg	1231B
522	Inj. Dactinomycin 0.5mg	1237A
523	Inj. Iopromide injection 50% w/v, 240 mg I/mL	1247A
524	Triclofos Oral Solution 500/5ml	1270A
525	Inj. Ephedrine Sulfate 50mg/ml	1326A
526	Inj. Tetanus Antitoxin 1500IU	1360A
527	Nicotine Gum 2mg	1380A
528	Nicotine Gum 4mg	1381A
529	Nebulise Hypertonic Saline 3%	1396A
530	Inj. Glycine Irrigation Solution 1.5% w/v	1401A
531	Inj. Vitamin A Palmitate 50000 IU/ml	1405A
532	Multivitamin Drops (Vitamin A (Concentrates Palmitate) IP 3000 IU +Vitamin D3 IP400 IU +Vitamin B1 HCL IP1mg +Vitamin B2-5-Phosphate Sodium IP1.5mg +Vitamin B6 HCl IP1.5mg +Vitamin B12 IP 2mcg +Niacinamide IP15mg +Zinc Sulphate IP 1mg +Manganese Sulphate IP 920mcg +Potassium Sulphate IP 3.5mg +L-Lysine HCl USP 24mg per 0.6 ml	1408A
533	Ferrous Ascorbate Drops 10mg/ml	1410AB
534	Inj. DTP+Hep-B+Hib Vaccine 0.5 ml	1445A
535	Proparacaine Hydrochloride Ophthalmic Solution USP 0.5%, 15ml	1464A
536	Patch Fentanyl Transdermal 100mcg/Hr.	1467A
537	Inj. Remdesiver 100 mg	1468A
538	Injection Drotavarine 40mg/2ml	1482A
539	Injection Pentamidine Isethionate 300mg, lyophilized, single dose vial	1496A
540	Injection Indocyanine green 25mg	1509A
541	Gentian Violet Paint Solution 0.5% v/v	1519A
542	Injection Granisetron 1mg/ml	1535A
543	Tab. Phenytoin Sodium 50mg	155A
544	Tab. Planosterone 0.5mg	1610A
545	Cap Molnupiravir 200mg	1652A
546	Inj. Fluorouracil 500mg	1723A
547	Diazepam rectal suppository 5 mg	1747A
548	Diazepam rectal suppository 10 mg	1747B

S.No	Item Name	Item Code
549	Tablet Deriphylline SR 450 mg	1756A
550	Mitomycin CInj. IP 2 mg	1955A
551	Inj. Lipid emulsion 20% Intravenous infusion	414A
552	Inj. Mannitol 20%	848A
553	Sterile Water For Injection	853A
554	Aerosol Spray Lidoocaine Hydrochloride Tropical 10%W/W	956A
555	Capsule Activated Charcoal 250mg	980A
556	Inj. Phenobarbital Sodium 130mg/ml	983A
557	Deferiprone 500mg	ED-001
558	Acyclovir Cream IP 5% W/W	[492]
559	Inj. Hydroxycobalamin 1mg/ML, 1ml Ampoule	1033A
560	Inj. Terlipressin 1mg/10ml, Each Amp/Vial	1064A
561	Tab. Bupropion Extended Release 150 Mg	1165A
562	Tab. Buprenorphine (Sub Lingual) 2mg	1173A
563	Inj. Phytomenadione (Vitamin K1) 1mg/0.5ml, 0.5ml Amp.	1187A
564	Tab Leucovorin Calcium 15mg	1231A
565	Inj. Filgrastim 300mcg (Recombinant Human Granulocyte Colony Stimulating Factor), 1ml Vial	1242A
566	Diatrizoate Sodium Oral Contrast Solution, 100ml Bottle	1248A
567	Inj. Levetiracetam 100mg/ML, 5 ML Vial	1288A
568	Inj. Anti Rabbits Vaccine, 1ml Vial	1361B
569	Nicotine Lozenges 2mg, Per Lozenges	1380B
570	Nicotine Lozenges 4mg, Per Lozenges	1381B
571	Anti-Cold Syrup [Paracetamol 125mg, Cpm 1mg, Phenylephrine 2.5mg, 60ml Bottle	139B
572	Inj. Hepatitis-B 10mcg, 0.5 ML, Per Vial/Ampoule	1446A
573	Proparacaine Hydrochloride Ophthalmic Solution 0.5%, 15ml Bottle	1464A
574	Paracetamol 250mg Suppository	1466A
575	Injection Factor-VIII Inhibitor Bypassing Agent (Feiba) 1000u, Per Vial	1478A
576	Tab Propranolol 20mg	1479A
577	Injection Drotavarine 40mg/2ml, Per 2ml Amp.	1482A
578	Injectin Fluphenazine 25mg, 1 ML Amp.	1488A
579	Tablet Misoprostol 100mcg	1523A
580	Injection Vitamin D3 (Cholecalciferol) (300000 Iu), 1ml Ampoule	1531A
581	Tab Stavudine (30mg), Lamivudine (150mg) And Nevirapine (200mg)	1533A
582	Inj. Imipenem And Cilastatin 500 Mg/Vial	1601A
583	Tab. B Complex, Per Tablet	1623A
584	Nonacog Beta Pegol 1000iu/Vial	1650A
585	Inj. Diclofenac Sodium 75mg/ML, Iv Bolus (1ml Amp)	1652A

S.No	Item Name	Item Code
586	Rurioctacog Alfa Pegol Factor Viii (Pegylated) 1000 Iu/Vial, Per Vial	1657A
587	Item Rurioctacog Alfa Pegol Factor Viii (Pegylated) 1500 Iu/Vial, Per Vial	1658A
588	Inj. Somatropin Biosynthetic-R-Dna Origin (Hgh), Pfs, 10mg/1.5ml , Per Pfs	1659A
589	Syrup Bromhexine Hydrochloride 4mg, 60ml Bottle	1782A
590	Injection L-Asparaginase 5000 Iu, Per Vial	337A
591	Inj. Vincristine 1mg/ML	348A
592	Inj Heparin 25000iu, 5ml Vial	373AC
593	Dried Factor Viii Concentrate Plasma Derived 250 Iu (Low Range), Per Vial	391A
594	Dried Factor Viii Concentrate Plasma Derived 500 Iu (Low Range), Per Vial	391B
595	Dried Factor Viii Concentrate Plasma Derived 1000 Iu (Low Range), Per Vial	391C
596	Dried Factor Ix Concentrate Plasma Derived 500, Per Vial	392F
597	Dried Factor Ix Concentrate Plasma Derived 600 Iu, Per Vial	392G
598	Recombinant Factor Vii-A 1mg, Vial [394A]	394A
599	Inj. Recombinant Human Erythropoietin 4000iu, 0.4ml Prefilled Syringe	402A
600	Inj. Recombinant Human Erythropoietin 2000iu, 1ml Prefilled Syringe	403A
601	Inj. Amiodarone Hydrochloride 50mg/ML, Per Amp.	410A
602	Inj. Human Anti D Immunoglobulin 300 Mcg	633A
603	Inj. Immunoglobulin 5% 100ml Bottle	635A
604	Anti Rabies Serum 1500 Iu/5ml, Per Vial	640A
605	Inj. Tetanus Toxoid 0.5ml, 0.5 ML Vial, Per Ampoule	646A
606	Tab. Thiamine 100mg	811A
607	Inj. Mannitol 20%, 500 ML Bottle	845A
608	Recombinant Coagulation Factor Vii A 2mg, 2ml Vial	932B
609	Inj. Hepatitis B Immunoglobulin 100iu/0.5ml, Per Vial	937A
610	Recombinant Third Generation Factor Viii (500 Iu) As Per Wfh Standard Guidelines, Vial	949A
611	Recombinant Third Generation Factor Viii (1000 Iu) As Per Wfh Standard Guidelines, Vial	949B
612	Recombinant Third Generation Factor Viii (1500 Iu) As Per Wfh Standard Guidelines, Vial	949C
613	Inj. Methylene Blue 10mg/ML, 10ml Vial	979A
614	Inj. Emicizumab 30mg/ML, Per Vial	AHD001
615	Inj. Emicizumab 60mg/0.4ml, Per Vial	AHD002
616	Inj. Emicizumab 105mg/0.7ml, Per Vial	AHD003

S.No	Item Name	Item Code
617	Inj. Emicizumab 150mg/ML, Per Vial	AHD004
618	Amphotericin B Inj. IP50mg, Per Vial	AHD005
619	Inj. Dexamethasone 4 Mg/ML (2ml Amp)	AVM001
620	Hand Sanitizer 500ml Bottle With Push Pump Fixable On Sanitizer Bottle. Containing Final Concentration As Ethanol 80% (V/V), Glycerol 1.45% (V/V), Hydrogen Peroxide 0.125% (V/V), Per Bottle Of 500ml	AVM003
621	Hand Sanitizer 100ml Bottle. Containing Final Concentration As Isopropyl Alcohol 75% (V/V), Glycerol 1.45% (V/V), Hydrogen Peroxide 0.125% (V/V), Per Bottle Of 100ml	AVM004
622	Hand Sanitizer 5 Ltr Pack. Containing Final Concentration As Ethanol 80% (V/V), Glycerol 1.45% (V/V), Hydrogen Peroxide 0.125% (V/V), Per Can Of 5 Ltr Pack.	AVM005
623	Inj. Tocilizumab Injection 400mg, Per Vial	AVM006
624	Inj. Tocilizumab 80mg, Per Vial	AVM007
625	Tab. Ivermectin 12mg	EDC01
626	Tab. Vitamin D3 (60000 Iu) (Chewing Tablet)	EDC02
627	Tab. Vitamin-C 500mg (Chewing Tablet)	EDC03
628	Cholecalciferol Sachet Vitamin D3 (60,000 Iu Per Gm), Each Sachet Of 1gm	EDC04
629	Lignocaine Hydrochloride 10% 50 ml pump Spray	EDL-0002
630	Lignocaine and Dextrose Injection IP 5%, 2ml Amp	EDL-0003
631	Injection Lignocaine and Dextrose (5%(hydrochloride) in 4 ml ampoule to be mixed with 7.5 % glucose solution)	EDL-0004
632	Glycopyrrolate Injection IP 0.2mg/ml, 5ml amp/vial.	EDL-0006
633	Glycopyrrolate Injection IP 0.2mg/ml, 20ml amp/vial.	EDL-0007
634	Etoricoxib Tab. IP90mg	EDL-0008
635	Paracetamol Pediatric Oral Solution.150mg/ml. 15 ml pack with dropper	EDL-0010
636	Paracetamol Dispersible Tab IP 250 mg	EDL-0011
637	Ketorolac Tromethamine Tab. IP10mg	EDL-0012
638	Mefenamic Acid Cap. BP20mg	EDL-0013
639	Mefenamic Acid Susp. 100mg/5ml	EDL-0014
640	Morphine Sulphate Injection IP 50mg/ml	EDL-0015
641	Morphine Sulphate Injection IP2mg/ml	EDL-0016
642	Morphine Sulphate Injection USP4mg/ml	EDL-0017
643	Tramadol Hydrochloride Tab. 100mg Prolonged Release IP	EDL-0018
644	Nalbuphine HCL Injection 10mg/ml	EDL-0019
645	Naproxen Tab. IP250mg	EDL-0020
646	Naproxen Tab. IP500mg	EDL-0021

S.No	Item Name	Item Code
647	Fentanyl Citrate Inj. IP 50mcg/MI10ml Amp	EDL-0022
648	ButorphanolTartarate Injection USP1mg/ml	EDL-0023
649	Methotrexate Tab. IP5 mg	EDL-0024
650	Dexamethasone Tab. IP 8mg	EDL-0027
651	Dexamethasone Tab. IP 16mg	EDL-0028
652	Levocetirizine Syrup IP 2.5 mg/ml	EDL-0030
653	Montelukast Sodium and Levocetirizine HCL Tab IP10mg+ 5mg	EDL-0031
654	Activated Charcoal Tab 500 mg	EDL-0033
655	Magnesium Sulphate Injection IP 50% (500mg/ 2 ml) W/V	EDL-0037
656	Suspension Phenytoin Oral Suspension IP 30mg/5 Ml	EDL-0038
657	Phenytoin Oral Suspension IP 125 mg/5 Ml	EDL-0039
658	Lamotrigine SR Tab. IP100 mg	EDL-0040
659	Lamotrigine SR Tab. IP 50 mg	EDL-0041
660	Clobazam Tab. IP 5 mg	EDL-0042
661	Ivermectin Tab. USP3mg	EDL-0043
662	Cefixime Oral Suspension IP 50 mg/5ml	EDL-0044
663	Cefpodoxime Drops IP 25 mg/ml	EDL-0045
664	Cloxacillin Inj.IP250mg	EDL-0046
665	Cloxacillin Cap. IP250 mg	EDL-0047
666	Cefuroxime Injection IP750 mg	EDL-0048
667	Cefuroxime Injection IP1 gm	EDL-0049
668	Norfloxacin TabIP 200mg	EDL-0050
669	Glycopyrrolate InjectionIP0.2mg/ml,1ml amp/vial.	EDL-0051
670	Dexamethasone Tab. IP 4mg	EDL-0052
671	Prednisolone Tab. IP2.5 mg	EDL-0053
672	Activated Charcoal Tab 650 mg	EDL-0054
673	Netilmicin Injection IP10mg/ml	EDL-0056
674	Netilmicin Injection IP 25mg/ml	EDL-0058
675	Netilmicin Injection IP 50mg/ml	EDL-0059
676	Netilmicin Injection IP 200mg/2ml	EDL-0060
677	Netilmicin Injection IP 300mg/3ml	EDL-0061
678	Nitrofurantoin Syrup BP25mg/5ml	EDL-0062
679	Sulfamethoxazole+Trimethoprim (Cotrimoxazole) Tab. IP800mg+160 mg	EDL-0063
680	Sulfamethoxazole +Trimethoprim (Cotrimoxazole) Suspension IP 200mg+40mg/5ml	EDL-0065
681	Sulfamethoxazole+Trimethoprim (Cotrimoxazole) Tab. IP400 mg +80mg	EDL-0069
682	Itraconazole Cap. BP200mg	EDL-0072
683	Acyclovir Suspension IP200mg/5ml	EDL-0073
684	Acyclovir Suspension IP400mg/ 5ml	EDL-0074
685	Acyclovir Eye Ointment IP3%.	EDL-0075

S.No	Item Name	Item Code
686	Acyclovir Eye Ointment IP5%.	EDL-0077
687	Valacyclovir IP Tab. 500mg	EDL-0078
688	Metronidazole Tab. BP250mg	EDL-0079
689	Metronidazole Tab. BP500mg	EDL-0080
690	Metronidazole Suspension BP125 mg/5ml	EDL-0083
691	Sumatriptan Tab. BP50mg	EDL-0085
692	Levodopa+ Carbidopa Tab. IP100mg+25mg	EDL-0086
693	Levodopa+ Carbidopa Tab. IP 250mg+25mg	EDL-0087
694	Iron with Folic Acid Syrup (Each 5ml contains : 30mg of elemental Iron, 550 MCG of Folic Acid)	EDL-0089
695	Iron Dextran Complex Injection IP 50mg/ml.	EDL-0090
696	Ethamsylate Tab. 200mg	EDL-0092
697	Diltiazem Tab IP 90mg	EDL-0094
698	Diltiazem Tab IP 120mg	EDL-0095
699	Isosorbide Mononitrate Tab. IP10mg	EDL-0096
700	Isosorbide Mononitrate Tab. IP 20mg	EDL-0097
701	Propranolol (SR) Tab.IP20 mg	EDL-0098
702	Propranolol (SR) Tab. IP 40 mg	EDL-0099
703	Verapamil Injection IP5 mg/ 2 ml	EDL-0100
704	Verapamil Tab IP 80 mg	EDL-0101
705	Verapamil Tab IP 120 mg	EDL-0102
706	Enalapril Injection USP 2.5 mg/ 2ml	EDL-0104
707	Nikorandil Tab. IP10 mg	EDL-0106
708	Ranolazine SR Tab 500 mg	EDL-0109
709	Trimetazidine (SR) Tab 20 mg	EDL-0111
710	Trimetazidine (SR) Tab. 30 mg	EDL-0112
711	Bosentan Tab. IP125 mg	EDL-0114
712	Streptokinase Injection IP750000 IU/ Vial	EDL-0116
713	Salicylic Acid Ointment IP3%	EDL-0117
714	Framycetin Cream 1%W/W	EDL-0118
715	Crotamiton Cream IP10%, 10gm	EDL-0122
716	Crotamiton Cream IP10%, 20gm	EDL-0123
717	Betamethasone (Dipropionate) Cream IP 0.05% W/W	EDL-0124
718	Fluticasone Nasal Spray IP 100 MD	EDL-0126
719	Lotion Coaltar 1% W/W Salicylic Acid 3 % W/V	EDL-0127
720	Permethrin Lotion 5 % w/v	EDL-0128
721	Povidone Iodine Gargle IP2 % w/v	EDL-0129
722	Hydrochlorothiazide Tab. IP25 mg	EDL-0131
723	Mannitol Inj. IP 20%	EDL-0132
724	Dutasteride Cap.IP0.50 mg	EDL-0134

S.No	Item Name	Item Code
725	Tamsulosin Tab. 0.4 mg	EDL-0135
726	Disodium Hydrogen Citrate Syrup 1.53mg/ 5ml	EDL-0136
727	Domperidone (DT) 5mg	EDL-0137
728	Doxylamine Succinate Tab. 25 mg	EDL-0138
729	Suspension Drotavarine (10mg/5ml),(20 mg/ 5 ml)	EDL-0141
730	Injection Drotavarine 20mg/2ml	EDL-0144
731	Tab. Drotavarine 80 mg IP	EDL-0145
732	Oral Drops Simethicone + Dill oil+ Fennel oil, 40 mg + 0.005 ml+0.0007 ml	EDL-0146
733	Gliclazide 60 mg IP	EDL-0147
734	Gliclazide 80 mg IP	EDL-0148
735	Injection Intermediate-acting insulin Lente 40 I.U/ ml.	EDL-0150
736	Clomiphene Citrate 25 mg IP	EDL-0151
737	Ethinyl estradiol 0.01 mg IP	EDL-0152
738	Ethinyl estradiol 0.05 mg IP	EDL-0154
739	Levonorgestrel + Ethinyl estradiol with Ferrous Fumarate 0.15 mg + 0.03 mg +75 mg IP	EDL-0155
740	Norethisterone (CR) 10 mg IP	EDL-0157
741	Levothyroxine Sodium 75mcg IP	EDL-0158
742	Carbimazole 10 mg IP	EDL-0159
743	Injection Anti-D Immunoglobulin 1500IU/ Vial IP	EDL-0160
744	Injection Succinyl choline 20 mg/ml IP	EDL-0165
745	Thiocolchicoside 4mg IP	EDL-0166
746	Thiocolchicoside 8mg IP	EDL-0167
747	Ointment Chloramphenicol 1%w/w,4gm IP eye ointment	EDL-0170
748	Eye Drops Moxifloxacin+ Dexamethasone 0.5%+0.1%w/v	EDL-0171
749	Eye Drops Ketorolac 0.5% w/v Tromethemine	EDL-0172
750	Eye Drops Neomycin Sulphate 3.5 mg+ polymyxin-B Sulphate 10000 units & Dexamethasone 0.1%/ml USP	EDL-0173
751	Eye Drops Natamycin 5%W/V IP	EDL-0174
752	Eye Drops Povidone Iodine 5%	EDL-0175
753	Ophthalmic solution Sodium Hyaluronate 0.1% w/v	EDL-0176
754	Nasal Drops Xylometazoline 0.1% IP	EDL-0177
755	Ear Drops Neomycin Sulphate 3.5 mg+ polymyxin-B Sulphate 10000 IU + Hydrocortisone 10 mg/ per ml,	EDL-0178
756	Saline Nasal Drops Solution 0.9 %, 0.65%	EDL-0179
757	Ear Drops Ofloxacin + Dexamethasone 0.3% w/v + 0.1% w/v Eye/Ear drop	EDL-0180
758	Betahistine 24 mg IP	EDL-0181
759	Progesterone 200mcg (Natural Micronized)	EDL-0182

S.No	Item Name	Item Code
760	Progesterone 300mcg (Natural Micronized) Cap	EDL-0185
761	Dinoprostone Gel 0.5 mg	EDL-0186
762	Ritodrine 10mg Hydrochloride IP	EDL-0187
763	Isoxsuprine Hydrochloride 10mg	EDL-0189
764	Tab. Alprazolam 0.25mg IP	EDL-0190
765	Disulfiram 500 mg IP	EDL-0191
766	Clonidine 150 mcg IP	EDL-0192
767	Tab. Salbutamol 4mg IP	EDL-0193
768	Syrup Levo salbutamol 1mg/5ml	EDL-0194
769	Levo salbutamol Inhalation MDI/ DPI 100mcg dose 50mcg	EDL-0196
770	Tab. Doxophylline 400 Mg IP	EDL-0197
771	Injectable IV solution Hydroxy ethyl starch Isotonic + Sodium Chloride 6gm+ 0.9gm (130/0.4) 6%+na.9%	EDL-0198
772	Water for Injection (Sterile) IP	EDL-0200
773	Injection Vitamin K11 mg/ ml Phytomenodione IP	EDL-0201
774	Methylcobalamine 500 mg IP	EDL-0202
775	Chloroquine (Phosphate) 150mg base IP/BP	EDL-0203
776	Ethambutol 400 mg IP	EDL-0204
777	Ethambutol 800 mg IP	EDL-0205
778	Isoniazid 100mg IP	EDL-0206
779	Isoniazid 300mg IP	EDL-0207
780	Pyrazinamide 500mg IP	EDL-0208
781	Pyrazinamide 750mg IP	EDL-0209
782	Rifampicin 150mg IP	EDL-0210
783	Rifampicin 450mg IP	EDL-0211
784	Syrup Rifampicin 100mg/5ml, IP	EDL-0212
785	Injection Streptomycin 1gm IP	EDL-0213
786	PAS Granules 1000MG, sodium Aminosalicylaie IP	EDL-0214
787	Ethionamide 250mg IP	EDL-0215
788	Clofazimine 50mg IP	EDL-0217
789	Clofazimine 100mg IP	EDL-0218
790	Dapsone 50mg IP	EDL-0219
791	Dapsone 100mg IP	EDL-0220
792	Injection Pentamidinsethionate 300mg	EDL-0221
793	Injection Bleomycinsulphate 15mg/ml	EDL-0222
794	Injection Flurouracil 50mg/ml IP	EDL-0223
795	Injection Vinblastin sulphate 10mg/ml USP	EDL-0224
796	Letrozole Tablet 2.5mg IP	EDL-0225
797	Injection G-MCSF (Macrophage) Inj. Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(GMCSF) 500 mcg	EDL-0226

S.No	Item Name	Item Code
798	Bicalutamide 50mg IP	EDL-0227
799	Injection Mitoantrone 20mg/10ml Mitoxontrone USP	EDL-0228
800	Injection Docetaxel 160mg/8ml IP	EDL-0229
801	Injection Recombinant Factor IX 500 IU Extended Half Life	EDL-0230
802	Gefitinib 250 mg IP	EDL-0231
803	Tamoxifen20mg IP	EDL-0232
804	Injection DPT 0.5ml/ amp	EDL-0233
805	Injection Hepatitis- B Immunoglobulin 200 IU vial/ 1ml.	EDL-0234
806	Injection Measels 0.5 ml, vial MMR IP	EDL-0235
807	Oral Solution Poliomyrlitis 0.1 ml, 20 dose vial IP	EDL-0236
808	Injection Iopromide 300mg/ml USP	EDL-0237
809	Injection Iopromide 379mg/ml	EDL-0238
810	Oral contrast Diatriazoate 76%	EDL-0239
811	Barium Sulphate Radio Opaque contrast	EDL-0240
812	Feracrylum Gel 1%w/w	EDL-0242
813	Azathioprine 25mg IP	EDL-0243
814	Tadalafil 40mg	EDL-0244
815	Sildenafil 25mg Citrate IP	EDL-0245
816	Sildenafil 50mg Citrate IP	EDL-0246
817	Sildenafil 100mg Citrate IP	EDL-0247
818	Injection Flumazenil 0.5mg/5ml IP	EDL-0248
819	Sodium Hypochlorite Solution containing chlorine not less than 6%	EDL-0249
820	Tab. Chlorpromazine Hcl IP 50mg IP	EDL-0250
821	Lamivudine+Nevirapine 150mg + 300mg IP	EDL-0251
822	Hydrogen peroxide solution 6%w/w, 500ml bottle	FDP-001
823	Ear/Eye Drop Each Ml Contains: Polymyxin-B Sulphate 5000iu+Chloramphenicol 4mg+Dexamethasone Sodium Phosphate 1mg, 5ml Lupolen Vial [FDP003]	FDP003
824	Bleaching Powder	FDP-004
825	Adhesive Plaster porus hypoallergentic with optimum adhesion and high tensile strength/USP/BPC. Size 10cmx10meters(SB); spool of 3 Rate to be quoted per piece)	DRM-009
826	Adhesive Plaster porus hypoallergentic with optimum adhesion and high tensile strength /USP/BPC Size 7.5 cmx10meters(SB);spool of 4 Rate to be quoted per piece)	DRM-010
827	Absorbable Gelatine Sponge based Topical Absorbable Hemostat without Formaldehyde, should be sterilized by dry heat. Size: 7cms x 5 cms x 1 cm	DRM-011
828	Absorbable Gelatine Sponge based Topical Absorbable Hemostat without Formaldehyde, should be sterilized by dry heat. Size: 7cms x 5 cms x 0.1 cm	DRM-012
829	Absorbable Gelatin Sponge based Topical Absorbable Hemostat without Formaldehyde, should be sterilized by dry heat. Size: 7cms x 5 cms x	DRM-013

S.No	Item Name	Item Code
	0.05 cm	
830	Oxidised Regenerated Cellulose based Topical Absorbable Hemostat Regular with Bactericidal property. Size : (2 x 3) inches	DRM-014
831	Oxidised Regenerated Cellulose Thicker Weave can be sutured through with bactericidal property. Size : (6 x 9) inches	DRM-017
832	Oxidised Regenerated Cellulose based Topical Absorbable Hemostat, Structured Non-woven material with bactericidal property. Ease of use in both open and minimally invasive procedures. Size : (4 x 4) inches	DRM-020
833	Cotton Elastic Crepe Bandage: Elastic 100% cotton bandage free of synthetic material with centre thread, no Lykra no viscoses. Should have adequate strength and good elasticity in every direction to exert uniform pressure on tissues. Should be washable. Size: 10cm x 4 mtr (stretched length).	DRM-021
834	Incise Drape : Sterile, breathable, adherent, polymeric film impregnated with iodophore. Should adhere securely to wound edges and provide continuous antimicrobial activity over several hours even during heavy retraction and irrigation. Usable with any preoperative skin preparation. Film should be uniformly impregnated with idophore. Size: 26 x 20 cm	DRM-026
835	Incise Drape : Sterile, breathable, adherent, polymeric film impregnated with iodophore. Should adhere securely to wound edges and provide continuous antimicrobial activity over several hours even during heavy retraction and irrigation. Usable with any preoperative skin preparation. Film should be uniformly impregnated with idophore. Size: 34-35 cm x 35 cm	DRM-027
836	Incise Drape : Sterile, breathable, adherent, polymeric film impregnated with iodophore. Should adhere securely to wound edges and provide continuous antimicrobial activity over several hours even during heavy retraction and irrigation. Usable with any preoperative skin preparation. Film should be uniformly impregnated with idophore. Size: 55-60cm x 45 cm	DRM-028
837	Incise Drape: Sterile, breathable, adherent, polymeric film impregnated with iodophore. Should adhere securely to wound edges and provide continuous antimicrobial activity over several hours even during heavy retraction and irrigation. Usable with any preoperative skin preparation. Film should be uniformly impregnated with idophore. Size: 60cm x 80 cm	DRM-029
838	Paraffin Gauze: Sterile with adequate quantity of paraffin. Uniformly impregnated. Size: 30 cm x 10 cm.	DRM-036
839	Adhesive Dressing Strip: With medicated gauze in the middle. Should be sterile: Size: Around 2cm x 7 cm.	DRM-037
840	Sterile eye pads: Oval shaped, 5-6 cm x 6-7cm size, sterile, single piece packing.	DRM-059
841	Sterile eye drapes: 100% polypropylene sheet, large size (100 x 100cm), insice area / adhesive area, 10 x 10 cm drain / fluid collection pouch, eye lid holders, malleable breath bar, sterile packing.	DRM-060
842	Silver Anti Microbial Dressing: Size: 5cms x 5 cms	DRM-074
843	Silver Anti Microbial Dressing: Size: 10cms x 10 cms	DRM-075
844	Silver Anti Microbial Dressing: Size: 10cms x 20 cms	DRM-076

S.No	Item Name	Item Code
845	Silver Anti Microbial Dressing: Size: 20cms x 20 cms	DRM-077
846	Silver Anti Microbial Dressing: Size: 20cms x 40 cms	DRM-078
847	Silver Anti Microbial Dressing: Size: 40cms x 40 cms	DRM-079
848	Nanocrystalline silver in Knitted polyester mesh dressing with Silcryst technology, 10cm x12.5cm	DRM-080
849	Nanocrystalline silver in Knitted polyester M&EQ mesh dressing with Silcryst technology, 10cm x 20cm Pack of 12	DRM-081
850	Nanocrystalline silver in Knitted polyester mesh dressing with Silcryst technology,, 20cm x 40cm	DRM-082
851	Nanocrystalline silver in Knitted polyester mesh dressing with Silcryst technology, 40cm x 40cm	DRM-083
852	Nanocrystalline silver in Knitted polyester M&EQ mesh dressing with Silcryst technology, 10cm x 120cm	DRM-084
853	Hydro Cellular Foam with ART Principle PU top M&EQ Layer with silicone gel, 12.5cm x 12.5cm	DRM-085
854	Hydro Cellular Foam with ART Principle Antibacterial PU top Layer with silicone gel, 17.5cm x 17.5cm	DRM-086
855	Hydro Cellular Foam with ART Principle Antibacterial PU top Layer with silicone gel 21cm x 21cm	DRM-087
856	Hydro Cellular Foam with ART Principle PU top M&EQ Layer with silicone gel, 10cm x 25cm	DRM-088
857	Hydro Cellular Foam with ART Principle PU top M&EQ Layer with silicone gel 10cm x 30cm	DRM-089
858	Hydro Cellular Foam with ART Principle PU top M&EQ Layer with silicone gel, 7.5cm x7.5cm	DRM-090
859	Paraffin Gauze roll 15Cm x 2 Mtr Box of 12- USFDA	DRM-091
860	Grid pattern acrylic adhesive film dressing 6.5x5cm Pkt of 100	DRM-092
861	Grid pattern acrylic adhesive film 15.5 x 8.5cm Pkt of 20	DRM-093
862	Grid pattern acrylic adhesive film 25 x 10cm Pkt of 20	DRM-094
863	Grid pattern acrylic adhesive film 35 x 10cm Pkt of 20	DRM-095
864	Nanocrystalline silver in Knitted polyester mesh dressing, 10cm x12.5cm	DRM-101
865	Nanocrystalline silver in Knitted polyester mesh dressing, 10cm x 20cm	DRM-102
866	Nanocrystalline silver in Knitted polyester mesh dressing, 20cm x 40cm	DRM-103
867	Nanocrystalline silver in Knitted polyester mesh dressing, 40cm x 40cm	DRM-104
868	Nanocrystalline silver in Knitted polyester mesh dressing, 10cm x 120cm	DRM-105
869	Hydro Cellular Foam Antibacterial PU top Layer with silicone gel, 12.5cm x 12.5cm	DRM-106
870	Hydro Cellular Foam Antibacterial PU top Layer with silicone gel, 17.5cm x 17.5cm	DRM-107
871	Hydro Cellular Foam Antibacterial PU top Layer with silicone gel 21cm x 21cm	DRM-108
872	Hydro Cellular Foam Antibacterial PU top Layer with silicone gel, 10cm x 25cm	DRM-109
873	Hydro Cellular Foam Antibacterial PU top Layer with silicone gel 10cm x 30cm	DRM-110
874	Hydro Cellular Foam Antibacterial PU top Layer with silicone gel, 7.5cm x7.5cm	DRM-111

ANNEXURE-D

(On firm's letter head)

ANNUAL TURN OVER STATEMENT

The Average Gross Annual Turnover of M/s. _____ address
_____ for the past three financial years are given
below and certified that the statement is true and correct

S.No.	Financial Years	Turnover in Lakhs (Rs)
1.	2021-22	-
2.	2022-23	-
3.	2023-24	-
Total		- Rs. _____ Lakhs

Average gross annual turnover - Rs. _____ Lakhs

Date

Signature of the bidder
Auditor/Seal
Accountant

Signature of
Chartered

(Name & Address.)
Tel. No.
Mob. No.

UDIN:

ANNEXURE-E

**PROFORMA FOR PERFORMANCE STATEMENT
(for a period of last 3 years)**

Name of the Laboratory:.....

Address:.....

S NO	Types of Samples Analyzed	No. of Samples Analyzed during		
		2021-2022	2022-2023	2023-2024
01.	Drugs/Fluids/Medicines etc.			
02.	Medical Devices Like, Surgical Sutures, Dressing Material, Disposables etc.			
03.	Implants			
04.	Devices			

Date: ... /.../ 2024.

Signature:

(Name in Capital) Name of the Lab:

Office Seal :

ANNEXURE-F

Affidavit

(on Non Judicial Stamp of Rs.100/-)

DECLARATION FORM

1. I (Name of the Bidder) S/O___, Age_, resident of____, am proprietor /Partner/ Director having our office at_ and the approved drug testing laboratory (Name)..... Situated at (Address)_do hereby declare that I have carefully read all the conditions of BID of Jammu and Kashmir Medical Supplies Corporation .J&K, for the BIDs floated for empanelment of approved drugs testing laboratories for analysis of drugs and other items for the year 2024-26 and shall abide by all the conditions set forth therein.
2. I further declare that I possess valid approval for testing of all the drugs/surgical& sutures for which Price Bid have been submitted by me/us in Cover B and permission on Form 37 have been obtained for testing of these items from State Licensing Authority where ever applicable.
3. That the approval to test drugs/surgical & sutures have been obtained on Form 37 bearing No._____which is valid/renewed up to_____.
4. That the Bidder firm is a sole proprietorship/Partnership/Pvt. Ltd./ltd. firm and following are the details of proprietor/partners/directors:-
S.No. Name of proprietor/ Partner/Director Age Present & Permanent Address Contact No.
5. That our laboratory/Firm/Company does not stand blacklisted /debarred or banned on any ground either by Bid Inviting Authority or Govt. of Jammu and Kashmir on the date of bid submission.
6. Our laboratory/Firm/Company also does not stand blacklisted, debarred or banned on the ground of wrong reporting of test results or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.
7. That I/we have carefully read all the conditions of bid in ref. **No. JKMSCL/ANALYTICAL TESTING LABS /2024/624.** for the empanelment of analytical testing laboratories for the test and analysis of Surgical & Sutures for the year 2024-26 for Jammu and Kashmir Medical Supplies Corporation and accept all conditions of bid, including amendments if any.
8. I/ we hereby declare that:
 - a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
 - b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
 - c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any

of the foregoing reasons;

- d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
 - e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition;
6. Our complete address for communication with phone no.-----
7. Email address :- _____
8. Bank detail for e banking :
Name of account holder
Full name of Bank with Branch
- A/c no. with full digits
IFSC code

Date:

(Deponent) Signature
Name of the Lab:

Office Seal:

Verification

I.....S/o.....(Designation)..... Prop/
Partner/ Director of Lab M/s Address.....Affirm on
oath that the contents/information from para 1 to 9 as mentioned above, are true &
correct to the best of my knowledge and nothing is hidden. I also declare on oath, that
if any information furnished by me as above is found wrong, false, forged or fabricated;
the Corporation will be at liberty to cancel the Bid and forfeiting the earnest money
deposit and or performance security, for which I shall be solely responsible and the
laboratory / firm may be Debarred/Banned/ prosecuted for the same

(Name of Deponent & Signature)
ATTESTED BY NOTARY PUBLIC

ANNEXURE – G

DETAILS OF LABORATORY

1. Name of the Laboratory & Full address:
Phone No (landline) :
Fax :
E-mail :
2. Other Branches & their Address (if any):
3. Whether the firm has its own manufacturing unit? : If yes give details of address, license number etc
4. Date of Start of testing of Drugs, Surgical &Sutures:
5. Approval No. & Date from competent Authority i.e. State Drug Controller
6. Valid up to :
7. Schedule L-1 certificate its no. and date of issue:
8. (i) NABL Accreditation no. & date
(ii) Scope of Accreditation
(iii) Its validity.
10. Name of the authorized signatory of Lab:
11. Specimen Signature of the authorized Signatory of Lab:
12. Names &Specimen Signatures of the approved Technical Staff who are authorized to sign the test reports:
 - (1) (Name) (Specimen Signature)
 - (2) (Name)

(Specimen Signature)

ANNEXURE - H(1)

PERSONNEL IN QC DEPARTMENT

Name of the Technical Staff approved by State Licensing Authority	Designation	Qualification	Experience (Experience relevant to analysis of drugs/surgical/sutures)

Signature of Issuing Authority:

Date:

Name:

Designation:

Name of the Lab:

Office Seal:

ANNEXURE – H (2)

LIST OF IMPORTANT EQUIPMENT/INSTRUMENTS/APPARATUS AVAILABLE IN THE LAB

SN o	Name of the Equipment Instruments / Apparatus	Make & Description	Date of Installation	Date of last Validation	Approval for testing of drugs from State licensing Authority since.....

Signature with Name of Issuing Authority:

Date:

Name of the Lab:

Office Seal:

Designation:

ANNEXURE – H (3)

FACILITIES IN THE MICROBIOLOGICAL SECTION

I. LIST OF STOCK CULTURES AVAILABLE

II. LIST OF EQUIPMENT / APPARATUS AVAILABLE WITH DATE OF INSTALLATION, make and approval from State Licensing Authority to permit microbiological testing in the Lab.

Signature:

Name of the Lab:

Date:

Official Seal:

ANNEXURE – H (4)

LIST OF REFERENCES SAMPLES ALONG WITH THEIR DATE OF PROCUREMENT

AND QUANTITIES, If required for any item.

Signature with Name:

Name of the Lab: Date:

Official Seal:

ANNEXURE-I

[on Rs. 100/- Non-Judicial Stamp Paper- "Affidavit"]

AGREEMENT

This deed of agreement is made on this day of 2024 between Jammu & Kashmir Medical Supplies Corporation Limited represented by its General Manager(P&S) having its Corporate Head Office at **Plot No 58, Friends Colony, Satyam Road, Trikuta Nagar Extension, Jammu** & Corporate Office Kashmir **Opposite State Motor Garages near Haj House Bemina, Srinagar** (herein after referred to as "First Party"(Purchaser) which term shall include its successor, representatives, executors assigns and administrator unless excluded by the contract) and M/s represented by its Proprietor/ Managing Director/ Managing Partner/ Authorized Signatory of the lab/ firm having its registered office at and its laboratory at (herein after referred to as "Second Party" (Laboratory) which term shall include its successor's representatives, heirs, executors and administrators unless excluded by the contract). Whereas the (Second Party) have agreed to conduct tests for First Party (Purchaser), for **drugs, medicines, surgical & sutures for the year 2024-2026** with specifications mentioned in the scheduled attached here to at the prices noted herein and in the manner and under the terms and conditions herein after mentioned and whereas the second party has agreed to deposit performances security to first party, equivalent to Rs 50,000 as per terms & conditions of the tender document in the form of bank guarantee for the due and faithful performance of this agreement, to be forfeited in the event of Second Party failing duly and faithfully to perform it. Now these present witness that for carrying out the said agreement in this behalf into execution the Second Party and the First Party (Purchaser) do hereby mutually covenant, declare, contract and agree each of them in the manner following, that is to say,

1. The term "Agreement", wherever used shall mean and includes the terms and conditions contained in the invitation to bid floated for the e-bid for the empanelment of analytical testing laboratories for the test and analysis of **drugs, medicines, surgical & sutures for the year 2024-2026** for Jammu & Kashmir Medical Supplies Corporation Limited (Rate Contract for Twenty Four(24) months period, extendable for another three (03) months with mutual consent) **JKMSCL/ANALYTICAL TESTING LABS /2024/624, dated 27-03-2024** and technical bid to be opened on **29 -04-2024** the instructions to bidders, the condition of bid, acceptance of bid, particulars herein after defined and those eligibility criteria, general conditions and other conditions that may be added from time to time.

2.1. The agreement is for the test and analysis of **drugs, medicines, surgical & sutures for the year 2024-2026**, by the Second Party (Laboratory) to the First Party (Purchaser), on terms and conditions set forth in the agreement.

2.2. This agreement shall be deemed to have come into force with effect from the date of receipt of letter of information/ acceptance and it shall remain in force up to a period of Twenty Four (24) months which can further be extended for another three (03) months with mutual consent of First Party and Second Party.

2.3. The bid quantity noted against each item in the schedule attached hereto indicates only the probable/ tentative total requirement of the First Party in respect of each item for the agreement period indicated in clause "2.2" above. This quantity may increase or decrease at the discretion of the First Party. The Second Party (Laboratory) shall conduct the tests of **drugs, medicines, surgical & sutures for the year 2024-2026** on the basis of requirement from time to time by the ordering authority of First Party (Purchaser-JKMSCL) specifying the quantity required to be tested.

2.4. The Second Party shall have no right/ query regarding testing against the tentative requirement mentioned in the schedule enclosed which may increase or decrease or First Party may not issue any order for quality testing.

2.5. The release of payment and deduction and penalties shall be as per terms and conditions of the tender document.

3. QUALITY TESTING ON THE RATE CONTRACT OF JKMSCL:

The Second Party shall in no case, use the rate contract of JKMSCL for quality testing and / or comparing of rates to/ with any of other department(s)/ agency(ies)/ NGO etc. In case Second Party do quality testing of any of the item(s) at the rate contract or provides the document for comparison of rates or otherwise, to any other department(s)/ agency(ies)/ NGO(s) etc, the defaulted Second Party shall have to pay 7.5% of the total invoice value of the products tested for other department(s)/ agency(ies) etc at the rate contract of JKMSCL as penalty to the first party (JKMSCL-purchaser) and further the Second Party shall be liable to be considered for Debarring/ Blacklisting for a period not less than five years.

4. TERMINATION OF CONTRACT ON BREACH OF CONDITION.

4.1. In case the empanelled laboratory fails or neglects or refuse to faithfully perform any of the covenants on his part herein contained, it shall be lawful for the First Party to forfeit the amount deposited by the laboratory (second party) as performance security and or other dues of 2nd Party available with 1st Party beside terminating the contract.

- 4.2. In case the Second Party (Laboratory) neglects or refuse to observe, perform, fulfill and keep, anyone or more or any part of any one of covenants, stipulation and provisions herein contained, it shall be lawful for the First Party, on any such failure, neglect or refusal, to put an end to this agreement. There upon on every article, cause and thing herein contained on the part of First Party shall cease and be void and in case of any damage, loss, expenses, differences in cost or any other from out of deposit/ due for the time being payable to the Second Party under this and/or any other contract shall be recovered from 1st Party. In case such last mentioned deposit/ dues are insufficient to cover all such damages, loses, expenses, difference in cost and other deposit as aforesaid, it shall be lawful for the First Party to **forfeit** the performance security made by the **1st Party** as herein before mentioned to reimburse all such damages, losses, expenses etc..
- 4.3. If any time during the course of contract it is found that the information furnished by the Second Party (Laboratory) to the First Party (JKMSCL) either in his bid or otherwise, is false, the JKMSCL may put on end to the contract/ agreement wholly or in part and thereupon the **provision of clause "4.1"** above shall apply or any other action are deemed fit by the First Party may also apply.
- 4.4. The First party (Purchaser-JKMSCL) reserves the right to terminate, without assigning any reasons the contract/ agreement either wholly or in part, without any notice to the Second Party. The Second Party shall not be entitled for any compensation what so ever in respect of such termination of the contract/ agreement by the First Party.
5. All certificates or notices or orders for time or for extra varied or altered suppliers which are to be the subject of extra or varied charges, whether so described in the Agreement or not, shall be in writing and unless in writing, shall not be valid, binding or be of any effect what so ever.
6. The Second Party (Laboratory) shall not be in any way interested in or concerned directly or indirectly with any of the officer, subordinate or servants of the First Party, in any trade, business or transaction nor shall the Second Party give or pay or promise to give or pay any such officer, subordinate, servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Second Party permit any person or persons whomsoever to interfere in the management or performance hereof under the Power of Attorney or otherwise without the consent in writing of the First Party obtained in first hand.
7. In case the Second Party (Laboratory) at any time during the continuance of the contract becomes bankrupt of or in solvent or commits any act of bankrupt or insolvency under the provisions of any law in that behalf for the time being

enforce or should compound with his creditors, it shall be lawful for the First Party to put an end to the agreement and there upon on every article, clauses and conditions herein contained to be operative on the part of the purchaser, shall cease and be void and the First Party shall have all the rights and remedies given to him under the preceding clauses.

8. SERVING OF NOTICE TO LABORATORY

- 8.1. All notice or communication relating to or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Second Party (Laboratory) if delivered to him or left at his/ her premises, place of business or abode.
9. And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises the decision of the Managing Director, JKMSCL in the matter shall be final and binding.
10. All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decided by first and the final appellant authority and decision of said authority shall be final.
11. All terms and conditions of the NIT shall be the part of this agreement.

Authorized signatory of the laboratory (Supplier)

Jammu & Kashmir Medical Supplies Corporation Ltd (First Party)
Represented by

(Second Party)
(Signature, Name & full Address with stamp)

General Manager (P&S)/ JKMSCL
(Signature, Name & full Address with Stamp)

Witness (Signature, Name & Address)

1.

2.

Witness (Signature, Name & Address)

1.

2.

ANNEXURE-J
(On Firm's letter head)
Memorandum of Appeal

Appeal no..... of..... Before the.....
(appellate authority)

1. Particulars of appellant:

- (i) Name of the appellant:
- (ii) Official address, if any:
- (iii) Residential address:

2. Name and address of the respondent(s):

- (i)
- (ii)
- (iii)

3. Number and date of the order appealed against and name and designation of the officer/ authority that passed the order (enclose copy), or a statement of a decision, action or omission of the procuring entity in contravention to the provisions of the Act by which the appellant is aggrieved:

4. If the appellant proposes to be represented by a representative, the name and postal address of the representative:

5. Number of affidavits and documents enclosed with the appeal:

6. Ground of appeal:
.....
.....
(supported by an affidavit)

7. Prayer:.....
.....
.....

Place

Dated

Appellant's signature